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Abstract 
 
A method was developed for analysis of natural and synthetic cannabinoids: THC, THC-
COOH, AM-2201, JWH-018 N4-hydroxypentyl and AB-CHMINACA. The method was 
validated based on UKIAFT, SWGTOX and ISO 17025 guidelines. The parameters that 
required validation were accuracy, precision, linearity, range, carryover, LOD, LOQ, 
recovery, matrix effect, repeatability, reproducibility, dilution integrity, selectivity and 
specificity, stability and robustness. Moreover, the method was validated based on Forensic 
Science Regulators guidelines and criteria, so it could be utilised in road traffic toxicology. 
The validation was successful for all five analytes, all analytes passed tested parameters. 
This LC-MS/MS technique can be utilised for the detection of THC in road traffic casework 
as it is in line with the Forensic Science Regulators guidelines for quantifying drugs under 
Section 5A of the Road Traffic Act 1988. This method also facilitates the analysis of SC, at 
concentrations typically detected in users and coronial cases associated with SC overdose. 
There is also the possibility to expand the method, to detect a wider range of drugs, by 
adding new SC to LC-MS/MS library, including new and emerging SC appearing in market. 
The validated method can be beneficial to analyse road traffic casework samples and SC 
concurrently, which can help to find out the prevalence and popularity of SC with the general 
population. In addition, the method was tested using clotted versus non-clotted blood, to 
test methods robustness.  The study looked at twenty clotted samples and 10 non-clotted 
samples, to find out what effects clotting has on THC and THC-COOH measured 
concentrations. The research seems to indicate that clotting of blood alters the measured 
concentrations of THC and THC-COOH. The results also indicate that the method is robust 
and can be utilised to analyse whole blood and clotted blood.     
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Abbreviations 
 
A&E – Accident and emergency 
ACN – Acetonitrile 
Amu – Atomic mass unit 
CAD – Collisionally activated dissociation  
CB1 – Cannabinoid receptor type one 
CB2 – Cannabinoid receptor type two 
CBD – Cannabidiol 
CBGA – Cannabigerolic acid 
CBN – Cannabinol  
CES – Carboxylesterase  
CID – Collision induced dissociation  
dMRM – Dynamic multiple reaction monitoring 
EDTA – Ethylenediaminetetraacetic acid 
EMCDDA – European Monitoring Centre for Drugs and Drug Addiction 
ESI – Electrospray ionisation 
FEWS – Forensic early warning system 
GABA – gamma aminobutyric acid 
GC-MS – Gas chromatography-mass spectrometry 
HCl – Hydrochloric acid 
ISO 17025 – International standard for testing and calibration laboratories 
LC – Liquid chromatography 
LC-MS – Liquid chromatography-mass spectrometry 
LC-MS/MS – Liquid chromatography-tandem mass spectrometry  
LOD – Limit of detection 
LOQ – Limit of quantitation 
ME – Matrix effect 
MeOH – Methanol 
MS – Mass spectrometry  
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NaOH – Sodium hydroxide 
NHTSA – National Highway Traffic Safety Administration 
NIDA – National Institute of Drug Abuse 
NPS – New psychoactive substances  
QC – Quality control 
QqQ – Triple quadrupole 
RE – Recovery   
RF – Radio frequency 
RTT – Road traffic toxicology 
SC – Synthetic cannabinoid(s) 
SPE – Solid phase extraction 
SWGTOX – Scientific Working Group for Forensic Toxicology 
TIAFT – International Association of Forensic Toxicologists 
THC – Δ9-tetrahydrocannabinol  
THCA – Tetrahydrocannabinolic acid 
THC-COOH – 11-nor-9-carboxy-THC (non psychoactive metabolite of Δ9 
tetrahydrocannabinol) 
UGT – Uridine 5`-diphosphoglucuronosyltransferase 
UKIAFT – United Kingdom and Ireland Association of Forensic Toxicologists 
UNODC – United Nations Office on Drugs and Crime 
UV – Ultraviolet  
V – Voltage 
WEDINOS – Welsh emerging drugs & identification of novel substances project 
WHO – World Health Organization  
WSA – Working solution a 
WSB – Working solution b 
WSC – Working solution c 
WSD – Working solution d 
WSF – Working solution f 
%CV – Coefficient of variance 
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11-OH-THC – 11-hydroxy-THC (psychoactive metabolite of Δ9-tetrahydrocannabinol)  
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1. Introduction 
1.1 Cannabis plant and history 
Cannabis sativa L. also known as marijuana, weed and pot has been used for cultural, 
medicinal and recreational purposes for centuries (Bonini et al. 2018). It first originated and 
was domesticated in central Asia (Bonini et al. 2018), where it was originally used as a fibre, 
food and for medicinal purposes (Antonio 2006). Only in recent centuries has cannabis 
become synonymous with recreational use (Chandra et al. 2017). Cannabis can be grown 
in almost all parts of the world and the plant can be male, female (Figure 1), as well as a 
hermaphrodite, which is bred for fibre production (Chandra et al. 2017). 
 
 
 
 
 
 
Figure11: Male (A) and female (B) cannabis sativa plants in the flowering stage. During the vegetative 
stage the sex of the plant cannot be determined. The male grows pollen sacs, which eventually burst 
and release pollen for fertilisation of female plant. The female flowers produce tiny white or orange hairs, 
called pistils, which are the female plant sex organ. When pistils come into contact with pollen, fertilisation 
occurs, seeds begin to develop. The unfertilised female flower is an area of interest for cannabis growers, 
it is where most resin with cannabinoids is made (Bonini et al. 2018). 
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For industrial farming of cannabis females’ plants are preferred, as they produce 
significantly higher quantities of the psychoactive cannabinoids than the male plant (Beckett 
el al. 2017). To ensure higher cannabinoid quantities in female plants they are often 
separated from male plants to avoid pollination (Chandra et al. 2017). Cannabinoids are 
made as a defence mechanism by the plant to protect against insects and predators (Bonini 
et al. 2018). The leaves, bract and stem of the plant is covered with trichomes, with female 
flowers having the highest amount of trichomes (Chandra et al. 2017). Trichomes produce 
cannabinoids and excrete them in resin (Figure 2). The main cannabinoid of interest is Δ9-
tetrahydrocannabinol (THC), which is the psychoactive substance in cannabis (Chandra et 
al. 2017). Cannabis contains THC and cannabidiol (CBD) as a mixture of mono-carboxylic 
acids, which become decarboxylated upon heating (Sharma et al. 2012). Figure 3 describes 
the conversion of THC and CBD from Cannabigerolic acid (CBGA) (Citti et al. 2018). The 
main forms and routes of administration for cannabis are summarised in Figure 4 and Table 
1. 
Figure22: Trichomes on cannabis surface (left picture), from the single heads of trichomes (right 
picture) cannabinoids are secreted in resin like material. Resin plays a protective function as is viscous, 
hydrophobic and has low volatility. It prevents water loss, deters animals, protects the plant from 
environmental damage (Chandra et al. 2017). 
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Figure 3: Biosynthetic formation of THC and CBD. CBGA is converted into tetrahydrocannabinolic acid 
(THCA) by THCA synthase enzyme or to Cannabidiolic Acid (CBDA) by CBDA synthase enzyme. Heat 
triggers a chemical reaction of THCA and CBDA and leads to decarboxylation of THCA and CBDA and 
formation of corresponding decarboxylated (neutral) species THC and CBD. Cannabinol (CBN) is formed 
from the oxidation of THC (Citti et al. 2018). 
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Table 1: Differences of preparation, concentration and route of administration for herbal, resin and 
oil forms of cannabis (Afsahi et al. 2016, Sharma et al. 2012). 
Form of 
cannabis 
Herbal cannabis 
(marijuana, ganja, 
charas) 
Resin cannabis 
(hashish, bhang) 
Cannabis (hash) 
oil 
Preparation To prepare herbal 
cannabis the plant 
leaves, stalks, 
seeds and 
flowering tops 
have to be dried.  
A traditional method of 
preparation is to rub fresh 
cannabis flower to gather 
resin by hands. 
Solvent extraction 
on cannabis resin is 
utilised. The extract 
(oil) looks like a 
dark viscous liquid. 
 
 
 
 
C 
Figure 4:  Physical representations of A - herbal cannabis, B - hashish, C - hash oil. The typical amount of 
THC in herbal cannabis is 10%, in hashish 20% and in hash oil up to 90% (Dotdash 2019) 
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Table 1: (Continued) 
Form of 
cannabis 
Herbal cannabis 
(marijuana, ganja 
and charas) 
Resin cannabis 
(hashish, bhang) 
Cannabis (hash) 
oil 
THC 
concentration 
Herbal cannabis 
has the lowest 
levels of THC (5-
10%).  
The THC concentrations 
in hashish are between 
herbal and hash oil 
concentrations (20%). 
 
Oil the highest 
amount of THC and 
is the most potent 
form of cannabis 
(80-90%). 
Route of 
administration 
Inhalation and 
smoked as joints. 
Consumed orally and 
infused in foods. 
Inhalation or oral 
consumption. 
 
1.2 Cannabis prevalence in the UK 
Cannabis is the most frequently used illicit drug worldwide and the most cultivated illegal 
drug in numerous countries (United Nations Office on Drugs and Crime (UNODC) 2019). It 
has been observed that the use of cannabis has increased globally in the decade from 2007 
to 2017, from 162 million users to 188 million users (UNODC 2019). Moreover, cannabis 
has become legal to use in several countries of South America, North America and Europe.  
Last year cannabis was the most used illicit drug in England and Wales (Home Office 
2019a). It is also the drug that was more likely to be repetitively used (Home Office 2019a). 
Cannabis was also the most confiscated drug by English and Welsh law enforcement in 
2018 (Home Office 2019b). In 2017 the majority of first-time entrants for drug treatment was 
cannabis related (European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
2019). For motorists in England and Wales the most commonly detected illicit drug was 
THC in the years 2010 to 2012 and 2015-2016 (Risk Solutions 2017, Rooney et al. 2017). 
The most frequent concentration of THC detected in blood in the period of 2010-2012 in 
motorists was 2-4ng/mL in 36.1% of 926 cases, followed by 1-2ng/mL in 28.4% of cases 
(Rooney et al. 2017). For over 60% of cases the THC concentration was above 2ng/mL, the 
Section 5A per se limit for drug driving in England and Wales (Rooney et al. 2017).  
In United Kingdom under The Misuse of Drugs Act 1971 cannabis is classified as a class B 
and Schedule I drug, therefore a licence is required to possess or distribute it (Home Office 
2019c). In 2019, Sativex (nabiximols), a cannabis-based medicine, which contains THC and 
CBD, was licenced for the treatment of multiple sclerosis related spasticity in England 
(Home Office 2019c).  
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1.3 Pharmacokinetics of THC 
The principle constituent and the psychoactive component of cannabis is THC (Baselt 
2015). Since the discovery of this compound in 1964 by Mechoulam and Gaoni there has 
been an ongoing interest in its pharmacology and potential medicinal use (Englund et al 
2012). 
THC is highly lipophilic, has a pKa value of 10.6 (acid) and binds strongly to lipoproteins in 
blood with approximately 90% of THC concentrated in the plasma (Baselt 2015). The main 
routes of administration for cannabis are either oral ingestion or smoking/inhalation (Baselt 
2015). The doses for smoking are typically 50mg of THC in a single cigarette and 
approximately 20-50mg in edibles, with an average THC concentration of 3.5-5% (Barrus 
et al.  2016, Hartman et al. 2016a, Vandrey et al. 2017). 
The bioavailability of THC is largely determined by the route of administration, this effects 
the blood concentration peak times and the onset of psychoactive effects. Smoking of 
cannabis results in an immediate sensation of euphoria colloquially known as a “high”. 
These effects are felt in within 5 minutes of smoking cannabis and taper off after 2-3 hours, 
though the overall the psychosomatic effects can last up to 4-6 hours (Huestis 2007, 
Grotenhermen 2003, Wolff et al. 2013). The bioavailability of THC via smoking can range 
from 2% to 56%, this is dependent on dosage, user’s technique of smoking (Huestis 2007). 
The peak concentration of THC if administered by inhalation is reached within 10 minutes, 
while the metabolites of THC are higher in blood concentration than the parent drug 30-45 
minutes after smoking (Huestis 2007, Hartman et al. 2016a). The detection window for THC, 
with a cut off limit of 0.5ng/mL, in plasma can range from 3-12 hours for lower doses (1.75% 
THC) and 6-27 hours for higher doses (3.55% THC) (Huestis 2007). Hartman et al. (2016a) 
found that the decrease in THC concentration relative to the maximum dose exceeds 90% 
in 4-8 hours when smoking. Schwope et al. (2011) found that peak THC concentrations are 
50ng/mL in whole blood after smoking 54mg of THC (Figure 5). Orally ingesting cannabis 
results in the initial euphoria and sedative effects occurring within 30-90 minutes. The peak 
psychoactive effect is felt after 1.5-3 hours, with the psychosomatic symptoms lasting up to 
6-8 hours (Vandrey et al. 2017). The bioavailability of the drug if taken orally is 10-20% 
(Huestis 2007). Administering cannabis orally delays the peak THC blood concentration, 
from 1-6 hours. In 1.5-6 hours the metabolites are higher in concentrations than THC 
(Vandrey et al. 2017). Vandrey et al. (2017) investigated orally consumed cannabis and a 
detection window of up to 8 hours in whole blood was demonstrated for THC, with a 
concentration cut off of 2ng/mL. This research also indicated that peak THC concentration 
did not exceed 5ng/mL in whole blood after oral use of cannabis at doses up to 50mg of 
THC (Figure 5). However, the volume of personal use needs to be considered when 
interpreting THC concentrations, as frequent users often have a baseline THC, ranging from 
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2.1-4.5 ng/mL and achieve higher peak THC concentrations with longer detection windows 
of up to 30 hours (Desrosiers et al. 2014). 
 
 
 
 
 
 
 
The half-life of THC is 20-57 hours for infrequent users and 3-13 days for frequent users 
(Baselt 2015). Such large variation is due to different study designs, their monitoring time, 
doses of THC and different cut off limits for detection. THC first distributes to perfused 
organs such as lungs, heart, brain, liver and afterwards to less vascularised organs and into 
fats. THC is highly lipophilic and accumulates in fat, from which it is later slowly released 
back into the bloodstream (Huestis 2007). This adds a further variable when trying to 
estimate THC concentrations in blood. 
THC is metabolised into over 100 metabolites (Grotenherman 2003). However, the primary 
metabolites are 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC (THC-COOH), 
(Figure 6) (Huestis 2007). Phase I metabolism of THC is hydroxylation by the hepatic 
cytochrome P450 enzyme family, mainly cytochrome P450 2C9 and cytochrome P450 34A 
(Huestis 2007). The product of THC hydroxylation is 11-OH-THC, which is a psychoactive 
metabolite and more psychoactively potent than THC. The concentration of 11-OH-THC is 
greater if cannabis is taken orally due to the more significant first past metabolism in the 
liver and degradation of THC in the stomach (Huestis 2007). 11-OH-THC is converted to a 
non psychoactive metabolite THC-COOH (Huestis 2007). Phase II metabolism of THC is 
the glucuronic acid addition to THC-COOH via the C11 carboxyl group (or phenolic hydroxyl 
group) by uridine 5`-diphosphoglucuronosyltransferase (UGT) (Figure 7) (Huestis 2007). 
THC is mainly metabolised in the liver, but metabolism may also occur in the brain, lungs, 
and intestine (Huestis 2007). 
Figure55: Differences in THC concentrations after smoking 54mg of THC (left) and oral 
ingestion of 50mg of THC (right).  If smoked the peak THC concentrations were 50ng/mL in 15 
minutes. With a concentration cut of 1ng/mL THC was detected for up to 6 hours and also at 22 
hour point (Schwope et al. 2011). After oral ingestion the peak THC concentration did not exceed 
5ng/mL (highest concentration measured in the research by Vandrey et al. 2017 for participants 
was 5ng/mL). With the concentration cut of 2ng/mL THC was detected for up to 8 hours (Vandrey 
et al. 2017). 
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About 70% of THC and its metabolites are removed from the body within 72 hours, they are 
mostly excreted in faeces (40%) and urine (30%) (Baselt 2015). The main metabolite of 
THC that is found in urine is THC-COOH-glucuronide and THC-COOH, with low amounts 
of THC and 11-OH-THC present. By contrast in faeces 11-OH-THC is the predominant 
compound (Huestis 2007). The clearance rates from plasma have been reported to be 
15L/hour for men and 12L/hour for women, it has also been suggested that clearance rates 
are 36L/hour for infrequent users and 60L/hour for frequent users (Sharma et al. 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THC 
(Psychoactive)  
THC-COOH 
(Non psychoactive) 
11-OH-THC 
(Psychoactive) 
CYP450 2C9 
CYP450 34A 
Oxidation 
Figure66: Phase I metabolism of THC. THC is hydroxylated by cytochrome P450 enzymes. A 
hydroxyl group is added to the 11th carbon of THC converting it to 11-OH-THC. 11-OH-THC is a 
psychoactive metabolite that is further metabolised by oxidation. An oxygen is added to the 11th 
carbon of 11-OH-THC making it THC-COOH, which is an inactive metabolite. 
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1.4 Pharmacodynamics of THC 
THC is a partial agonist that binds to G-coupled-protein receptors cannabinoid receptor type 
one (CB1) and cannabinoid receptor type two (CB2), CB1 is primarily located in the central 
nervous system and CB2  on immune cells (Grotenhermen 2004). THC has the same affinity 
for CB1 and CB2 but higher efficacy for the CB1 receptor (Pertwee 2008). The exact 
mechanism of action that underlies THC’s interaction with the CB1 and CB2 receptors are 
unclear but it appears to affect a wide range of neurotransmitters. It has been postulated 
that THC’s interaction with CB1 and CB2 receptors results in inhibition of adenylate-cyclase, 
this in turn inhibits the release of the neurotransmitters, acetylcholine and glutamate while 
indirectly affecting opioid and serotonin receptors (Oberbarnscheidt and Miller 2017). 
Activation of the CB1 receptors also modulates the transmission of other neurotransmitters 
THC-COOH 
(Non psychoactive )  
THC-COOH-glu 
(Non psychoactive )  
UGT   
Figure 7: Phase II metabolism of THC. The second phase of metabolism is glucuronidation, this is a 
biotransformation reaction in which a glucuronic acid is added to the compound, increasing 
hydrophilicity. This allows easier elimination from the body via urine or faeces. THC-COOH interacts 
with UGT which transfers glucuronic acid to THC-COOH. The product of the reaction is glucuronide 
THC-COOH-glu.    
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such as dopamine, gamma aminobutyric acid (GABA), histamine, glycine, noradrenaline 
and neuropeptides (Grotenhermen 2004).  
CB1 and CB2 are known as the endocannabinoid receptors and together with endogenous 
ligands make up the endocannabinoid system (Grotenhermen 2004). THC`s chemical 
structure is similar to anandamide, a natural CB1 ligand. The endocannabinoid system has 
several functions, modulating cardiovascular effects, smooth muscle contraction, liver, 
gastrointestinal tract, the immune system and the reproductive system. Recent research 
has also indicated that CB1 and CB2 receptors may be present in the respiratory tract and 
urinary system (Maccaroone et al. 2015).  
Activation of CB1 by THC induces feelings of euphoria and relaxation, in addition to sensory 
intensification (Bloomfield et al. 2019). At high doses THC can induce anxiety, panic attacks, 
increased heart rate/blood pressure, a decrease in intraocular pressure, enhanced appetite, 
impairment of memory, learning and motor coordination (Bloomfield et al. 2019). A summary 
of commonly observed THC effects in pharmacological studies is presented in Table 2 with 
the different brain regions affected by THC displayed in Figure 8. Chronic use of THC is a 
risk factor for schizophrenia, psychotic disorders, depression and dependency (Bloomfield 
et al. 2019). Cannabis use during adolescence, a key period in CNS development, may 
have long term effects on emotion, cognitive function, memory and addiction (Bloomfield et 
al. 2019, National Institute of Drug Abuse (NIDA) 2019). Drummer et al. (2019) suggests 
THC may cause increased risk of myocardial infarction, strokes and may also be a 
contributory factor or a direct cause of death, although, it appears that this phenomenon is 
rare (EMCDDA 2019). 
 
Table 2: Observed THC effects in pharmacology studies (Grotenhermen 2004, Bloomfield et al. 
2019, Colizzi and Bhattacharyya 2018). 
Body systems, organs THC effect 
Mental state and behaviour Relaxation, anxiety, panic, impairment of learning and 
memory, reduced reaction time, fatigue, euphoria, 
dysphoria, reduced anxiety, hallucinations, alteration 
of time perception, fragmented thinking, ataxia, 
weakness, unsteady gait and paranoia. 
Nervous system Increase of appetite, neuroprotection in ischemia and 
hypoxia, analgesia, vomiting, anti-emetic effects and 
psychosis. 
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Table 2: (Continued) 
Body systems, organs THC effect 
Cardiovascular system Increased heart rate, decrease or increase in blood 
pressure, enhanced heart activity, inhibition of platelet 
aggregation, myocardial infarction and stroke. 
Eye Decrease of intraocular pressure, reduced tear flow 
and reddened conjunctivae. 
Body temp Decrease or increase in body temperature. 
Immune system Anti-inflammatory, anti-allergic effects and decreased 
resistance towards pathogens and carcinogens. 
Genetic material Inhibition of DNA, RNA and protein synthesis, 
influence cell cycle and antineoplastic activity. 
Reproductive system Reduced sperm count, motility, suppressed ovulation 
and disturbed menstrual cycle. 
Respiratory system Bronchodilation and dry mouth. 
 
 
Figure 8: Brain areas and their functions. Cannabinoid receptors CB1 are found in several brain areas 
and are activated by THC. Different brain regions produce different effects when interacting with THC. 
The following are common effects after receptor activation with THC. Cerebellum, loss of balance and 
motor coordination. Hippocampus, impairment of memory and learning. Neocortex, fragmented 
thinking, difficulty on focusing. Brain stem and spinal cord, prevention of nausea. Amygdala, elevation 
or reduction of anxiety. Ventral striatum, feeling of “high”. Basal ganglia, relaxation, calmness. 
Hypothalamus, increased appetite (NIDA 2019). 
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Tolerance for THC can develop rapidly following during chronic use, thereafter acute effects 
of THC are less prominent. The current research suggests that cognitive functions of verbal 
memory, divided attention and reaction time show the highest tolerance levels (Colizzi and 
Bhattacharyya 2018, Ramaekers et al. 2016). The dependency/addiction to cannabis is 
known as cannabis use disorder (Bloomfield et al. 2019). Studies suggest that 
approximately 9% of people using cannabis can become dependent on it, while 17% of 
those who begin usage in adolescence can develop cannabis use disorder (NIDA 2019). 
THC withdrawal symptoms are relatively mild with most severe effects being anxiety, 
headaches, nausea, nightmares, insomnia, reduced appetite and depression lasting to 
around 4-14 days (Oberbarnscheidt and Miller 2017). 
 
1.5 Synthetic cannabinoids 
1.5.1 History and legal status in the UK 
Synthetic cannabinoids (SC) also colloquially known as “Spice” in Europe or “K2” in the US, 
are CB1 and/or CB2 agonists. In the 1990s research was being carried out to develop THC 
analogues for pharmaceutical therapies by Professor John W. Huffman in Clemson 
University and at the same time by Professor Alexandros Makriyannis in Norheastern 
University (Wiley et al. 2011).The focus of their research was into the development of CB1 
and CB2 agonists for medicinal purposes. However, the developed drugs were often more 
psychoactive than THC and not safe to use therapeutically (De Luca and Fattore 2018). It 
is likely that the research published during this time was the basis for illicit manufacturers 
to develop SC (Wiley et al. 2011). 
The first SC appeared in 2004 in Europe and the first detected SC was JWH-018 (AM678) 
in Germany in 2008 (Wiley et al. 2011, UNODC 2013). JWH-018 was one of the chemicals 
synthetized by Professor John W. Huffman in 1990s, and derived its name from his initials, 
as did the AM chemicals, which were synthesised by Professsor Alexandros Makriyannis. 
SC popularity was originally due to its legal status, cheapness and ease of purchase (Rojek 
et al. 2017). SC could be purchased via the internet or in “head shops”, where it was typically 
sold as a product marked “not for human consumption”, with the actual contents not known 
(EMCDDA 2017a). In 2016 the Psychoactive Substances Act 2016 came into effect to 
control all new psychoactive substances. Prior to this, succeeding amendments to Misuse 
of Drugs Act 1971 were passed by UK government to regulate SC. In 2009 the first 
amendment was passed for “first generation” SC, in 2013 a second amendment for “second 
generation” SC and in 2016 third amendment for “third generation” SC. The succeeding 
amendments were needed as the manufacturers could circumvent the legislation by simple 
alterations to the SC structure. 
Previously under the UK law drugs were under “generic” control, their core structure and 
specific modifications, and substitutions were controlled by law. By altering and adding a 
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substitute that was not illegal, a new compound could be made without contravening the 
existing drug legislation. JWH-018 was made illegal in 2009, as a result the manufacturers 
added halogen atoms to the side chain attached to the indole nitrogen atom. This new 
compound was not JWH-018 and therefore not controlled under the drug legislation, this 
resulted in the synthesis of a new compound, AM-2201 (fluorinated JWH-018) which was 
legal until 2013 (Home Office 2015). Retrospectively, it can be argued that this strategy of 
legislating SC in this fashion led directly to the development of more potent second and 
third generation SC as manufacturers altered the structure to avoid legal controls. 
Conversely these alterations led to an increased binding affinity for the new generation SC 
and the CB1 and CB2 receptors, this in turn increased the psychoactive and addiction 
potential of the new generation SC’s. 
1.5.2 SC recreational use 
Like cannabis the most common route of administration for SC is inhalation. Plant material 
is infused by spraying or soaking it with an organic solution of SC and evaporating the 
solvent (UNODC 2013). The distribution around the plant material is not always 
homogenous and “hot pockets” may be present, these are areas where the SC solution are 
more concentrated (EMCDDA 2017a). SC can also be present in the solid, crystalline 
powder (UNODC 2013), while in recent years SC have been developed in e-liquids for 
vaping. Moreover, in UK prisons SC are frequently smuggled in by letters, pictures or 
drawings with the paper infused with the psychoactive chemicals (Ford and Berg 2018). 
Figure 9 demonstrates the physical forms, in which SC are routinely found in. 
 
 
 
 
 
 
 
 
 
 
 
 
 
B A 
C 
D 
Figure 9: Physical forms of SC. A – Infused plant material, it is used by smoking. B - Adulterated e-
liquid, it is used by inhalation. C - Powder form, it is snorted or swallowed. D – Letters infused with SC, 
to  avoid detection in prisons, they are used by smoking (EMCDDA 2017a, Ford and Berg, 2018). 
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1.5.3 SC prevalence and most common SC’s in the UK 
The usage of new psychoactive substances (NPS) seems to have decreased since the 
passing of the Psychoactive Substances Act 2016 (Figure 10) (Home Office 2018b). 
However, there are still ongoing issues with SC in the UK particularly in economically 
vulnerable groups such as prisoners, young people, homeless and individuals from low 
income backgrounds (Her Majesty`s Inspectorate of Prisons 2018, EMCDDA 2017a). Two 
of the major incentive for SC as drugs of abuse is that they are frequently not detected in 
standard toxicological screenings and are more potent than THC (Gurney et al. 2014, Rojek 
et al. 2017, Tai and Fantegrossi 2014). It was reported that in 2018/2019 only 0.5% of adults 
(approximately 152,000 people) used any NPS, with the major group being SC (Home 
Office 2019a). It is most likely this number is an under estimation, as these surveys rely on 
self-reporting, in addition the majority of forensic laboratories do not screen for SC. 
Currently in the EU there is over 160 SC that have been detected and are present in 
circulation, with the number increasing every year (EMCDDA 2017a). 
The last forensic early warning system (FEWS) report in the UK for 2016/17 found that the 
most common SC were 5F-ADB(5F-MDMB-PINACA) and MDMB-CHMICA (Home Office 
2018a). The Welsh emerging drugs & identification of novel substances project (WEDINOS) 
monitors novel psychoactive substances, submitted from across the UK. A report by 
WEDINOS for the period of April 2018 to 2019 March found that 5F-ADB and AMB-
FUBINACA were the most common SC identified in samples (Public Health Wales 2019). 
It was noted that there was an increase in the prevalence of 4F-MDMB-BINACA from 
December 2018 to March 2019 (Public Health Wales 2019). 
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Figure 10: The Crime Survey for England and Wales for 16 to 59-year olds report of use of NPS. In 
2015/16 approximately 244000 people were using NPS. After the Psychoactive Substance Act 2016 
the number of people using NPS decreased in 2016/17 to approximately 143000 people, which was 
a significant decrease. The following year 2017/18 approximately 121000 were using NPS similar to 
previous year, no significant change was seen (Home Office 2018b). 
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1.5.4 General pharmacology for SC 
Unlike THC, SC are relatively new and do not have extensive research, on their 
pharmacological and toxicological effects. (Presley et al. 2016). In addition, there are over 
160 SC, with new drug variants of evolving chemical structure constantly emerging. These 
new SC compounds can have a lifespan of as little as 12 months in the market (Presley et 
al. 2016, Marusich et al. 2018). As a result most of the information regarding SC is 
established by in vitro cell culture studies and in vivo animal models. The majority of 
toxicological data in humans concerning SC is derived from accident and emergency (A&E), 
case studies, which are summarised in Table 3 (Gurney et al. 2014). 
 
Table 3: Observed effects of SC on different systems (Gurney et al. 2014, Behonick et al. 2014, 
Rojek et al. 2017, Tai and Fantegrossi 2014 and EMCDDA 2017a) 
Parameter SC effects 
Kidney Acute kidney injury. 
Gastrointestinal Vomiting, nausea and abdominal pain. 
Cardiovascular Increased heart rate, high blood pressure, chest pain, 
cardiovascular toxicity, stroke and heart attack. 
Dermal Rash and itchy skin. 
Neurological Agitation, confusion, dizziness, drowsiness, hallucinations, 
seizures, tremors, blurred vision, dilated pupils, 
paranoia,psychosis, suicidality, anger, sadness, blackouts, 
restlessness, numbness, altered mood and time perception, 
bloodshot eyes, dryness of mouth, panic attacks, short term 
memory defects, delusions, excessive sweating, slurred speech, 
delayed reactions and loss of memory. 
 
The user desired effects of SC are mood elevation, euphoria, relaxation (Gurney et al. 
2014). Unlike THC, SC are full agonists at CB1 and the euphoria associated with the drug, 
is more potent, however the overall effects is shorter and typically only last for up to 2 hours 
(Behonick et al. 2014). Based on in vitro assays SC have higher binding affinity to CB1 and 
CB2 compared to THC. (Gurney et al. 2014). It has been proposed that the first generation 
SC have approximately 10 times the potency of THC for the CB1 receptor, while the latest 
generation products are over 100 times more potent than THC.  
Due to this increased potency dependence syndrome is more likely to develop for users of 
SC (Fantegrossi et al. 2014, Tai and Fantegrossi 2014). Moreover, the withdrawal 
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symptoms for SC are far more severe than those of THC. Users have been reported to 
experience tremors nausea, vomiting, insomnia, headache, seizures, hallucinations 
(Gurney et al. 2014, Tai and Fantegrossi 2014). Unlike natural cannabinoids SC have been 
more closely linked to fatalities. Deaths associated with SC have been reported in the USA, 
Poland, Russia and UK (EMCDAA 2017). AB-CHMINACA has recently been the SC linked 
to fatalities in UK, with the parent structure or its metabolites confirmed in post-mortem 
samples (EMCDAA 2017b). 
Due to the high volume of SC available and the limited toxicological data, the metabolism 
of these drugs is not widely understood, especially for the new generation SC. Despite this 
the general metabolism of SC involves the hydroxylation, keto-oxidation, carboxylation, 
dehalogenation and hydrolysis of the parent compound by cytochrome P450 isoenzymes, 
(Presley et al. 2016). The main isoenzymes, that produces the highest amount of 
metabolites by oxidation, are CYP1A2, CYP2C9, CYP3A4, CYP2B6 (Presley et al. 2016). 
The defluorination is attributed to cytochrome P450 2E1. Carboxylesterase (CES) enzymes 
perform the hydrolysis, with CES1 being the major enzyme responsible.  UGT is responsible 
for the glucuronic acid conjugation, with UGT1A1, UGT1A9, UGT2B7, UGT1A3, UGT1A10, 
UGT1A7 being major enzymes involved in the metabolism of SC (Fantegrossi et al. 2014, 
Presley et al. 2016). The metabolites of SC can be full or partial agonists at CB1 receptor 
and produce synergetic effects with the parent compound, thereby increasing the potency 
of the user desired effects (Presley et al. 2016).  Moreover, it was reported that SC MAM-
2201 was found in high concentrations in adipose tissue, suggesting that SC may be able 
to accumulate in fat of the body, like THC (Presley et al. 2016). 
1.5.5 Pharmacology of JWH-018, AM-2201 and AB-CHMINACA 
JWH-018, a first generation SC, is metabolised by CYP1A2 and CYP2C9 enzymes. JWH-
018 produces several metabolites, the main metabolites  are JWH-018 N-(3-OH-pentyl), 
JWH-018 N-(4-OH-pentyl), JWH-018 N-(5-OH-pentyl), JWH-018 pentanoic acid, JWH-018 
(5-OH-indole), JWH-018 (6-OH-indole) (World Health Organization (WHO) 2014). The 
second phase of metabolism is glucuronidation via the UDP enzymes UGT1A1, UGT1A9 
and UGT2B7. The glucuronic conjugates are afterwards excreted by urination. The 
metabolites of JWH-018 are psychoactive and can produce synergistic effect with the parent 
drug (WHO 2014).  The maximum concentrations of JWH-018 detected in blood are less 
than 5ng/mL (Kacinko et al. 2011, Öztürk et al. 2015). 
AM-2201 is lipophilic second generation SC and is also a full agonist at CB1 receptor (Figure 
11). Like JWH-018 the same issues of toxicity are associated with AM-2201, the 
pharmacology of AM-2201 is also similar to JWH-018. The metabolism for AM-2201 is 
almost identical as for JWH-018, with the same enzymes being involved in the breakdown 
of the parent compound and related metabolites. The major AM-2201 metabolites are AM-
2201 N-(4-hydroxypentyl), AM-2201 6`-hydroxyindole, JWH-018 N-(5-OH-pentyl), JWH-
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018 pentanoic acid JWH-073 N-(4-OH-butyl), JWH-073 butanoic acid (Figure 12). Typically, 
the concentrations of AM-2201 detected in blood does not exceed 5ng/mL and for 
metabolites it ranges from 0.1 to 12ng/mL (Carlier et al. 2018), while the dependence risk 
and withdrawal symptoms of AM-2201 is similar to that of JWH-018. 
 
JWH-018 AM-2201 
AB-CHMINACA THC 
Figure 11: Structures of different generations of SC and of THC. JWH-018 is a “first generation” SC and is 
an aminoalkylindole (the core of it is an indole, has a pentyl tail, methanone link section and a naphthyl ring). 
It has 8 times higher binding affinity at CB1 receptor than THC. AM-2201 is a “second generation” SC and is 
a fluorinated aminoalkylindole (the core of it is an indole, methanone link section, naphthyl ring and a 5-
fluoropentyl tail). AM-2201 is the fluorinated version of JWH-018 and has higher binding affinity to CB1 
receptor than JWH-018. AB-CHMINACA is a “third generation” SC and an indazolecarboxamide (the core of 
it is an indazole, carboxamide link section, carbamoyl substitution and a cyclohexylmethyl tail). AB-
CHMINACA is reported to have 4 times higher binding affinity to CB1 receptor than JWH-018. THC is a natural 
cannabinoid (made of three rings, phenol, pyran, cyclohexane, an alkyl tail), whose effects the SC 
cannabinoids mimic, when they interact with CB1 receptors. THC is a partial agonist at CB1 receptor, while all 
of the mentioned SC are full agonists at CB1. 
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  Figure 12: The metabolic pathway of AM-2201 and JWH-018. The notations + (agonist), -
(antagonist), x (no binding affinity), ? (unknown). AM-2201 and JWH-018 are metabolised 
similarly, as AM-2201 is a fluorinated version of JWH-018. JWH-018 and AM-2201 are both 
full agonists at CB1 and CB2, several metabolites are also agonists at the cannabinoid 
receptors. The enzymes responsible for metabolism are mainly CYP1A2 and CYP2C9. 
Examples of metabolites produced only by AM-2201 are AM-2201 N-(4-hydroxypentyl), AM-
2201 6`-hydroxyindole, by only JWH-018 is JWH-018 N-(3-OH-pentyl. Both SC have same 
metabolites JWH-018 N-(5-OH-pentyl), JWH-018 pentanoic acid JWH-073 N-(4-OH-butyl), 
JWH-073 butanoic acid. Second phase of metabolism is the glucuronidation followed by 
excretion of the metabolites in urine (Fangetrossi et al 2014). 
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AB-CHMINACA is a lipophilic third generation SC and is a full agonist at CB1 receptor 
(Figure 11). AB-CHMINACA is 16 times more potent than THC. There is a high risk of acute 
toxicity with AB-CHMINACA, with even less toxicity data relating to this SC compared to 
JWH-018 and AM-2201. The reported adverse effects for AB-CHMINACA are 
depersonalisation, distorted perception of time, impaired motor performance, hallucinations, 
paranoia, confusion, fear, anxiety, dry mouth, “red eyes”, tachycardia, nausea, 
hyperemesis, delirium and violent behaviour. More severe effects include rapid loss of 
consciousness/coma, myocardial infarction, stroke, psychosis seizures and convulsions. At 
least 31 fatalities have been associated with AB-CHMINACA from the period of 2014 and 
2017 (WHO 2017). 
In vitro studies of AB-CHMINACA metabolism suggested there is up to 26 metabolites 
produced and the majority of these were confirmed in urine samples from AB-CHMINACA 
users (Erratico et al. 2015).The metabolites observed in urine samples were M1-M7, M9M 
M11, M21, M25 and M26 (Erratico et al. 2015, WHO 2017). Six mono-hydroxylated 
metabolites (M9-14) and six di-hydroxylated metabolites (M2-M7) are produced by CYP 
enzymes. The major enzyme of CYPs involved in the metabolism is CYP3A4, with minor 
contribution from CYP2D6, 2C9, 2C19, 2B6, 1A2. N-dealkylation of AB-CHMINACA by 
CYPs enzymes produce the M8 metabolite, which is further hydroxylated into M1 by CYPs. 
Two deaminated metabolites (M20, M21) are produced by amidase enzymes. M21 
undergoes further metabolization by CYPs enzymes and produces mono hydroxylated 
metabolites (M15-M19). Glucuronidation for AB-CHMINACA metabolites by UGT enzymes 
results in 5 glucurinidated metabolites: M24 formed from M20, M25 and M26 formed from 
M21, and M22 and M23 formed from M14-M19. The typical concentrations of AB-
CHMINACA in blood are low, with the highest reported concentrations to be below 5ng/mL 
for antemortem samples and for post-mortem samples the concentration ranged between 
0.32 and 12ng/mL (median 3.7 ng/mL) (EMCDDA 2017b). The dependence risk of AB-
CHMINACA is high, due to its short-lasting effects and potency with withdrawal symptoms 
being similar to those as described for JWH-018 (WHO 2017). 
 
1.6 Liquid chromatography-tandem mass spectrometry (LC-MS/MS)   
Liquid Chromatography (LC) is a separation technique in which liquid mobile phase flows 
through solid/liquid stationary phase. The separation occurs based on partition and 
adsorption principles with the former being liquid-liquid chromatography and the latter liquid-
solid chromatography (Agilent, 2016). The partition separation occurs as different analytes 
partition separately between mobile and stationary phases, which leads to different rates of 
migration. In adsorption separation, analytes adhere to the stationary phase at different 
strengths, which means those that adhere more strongly take longer to elute, and hence 
have a longer retention time (Bayne 2010). The schematic of a typical LC system and is 
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workflow is shown in Figure 13. Compounds can be detected by utilising ultraviolet (UV) 
detector coupled with a known retention time or for more quantitative and definitive analysis 
LC units can be coupled with mass spectrometer (MS) systems. MS is a powerful analytical 
technique used for quantitative and qualitative applications. The basic principle, of the mass 
spectrometry is illustrated in Figure 14. 
 
 
Figure 13: A basic workflow of a LC system. The mobile phase A is typically water with or without 
buffers and B is an organic solvent, for example methanol, with or without buffer.  The mobile phases 
are pushed throughout the system by the pump. The pistons in the pump draw solvents from bottles 
to pulse damper, to the mixing chamber, purge valve and finally column. Sample is injected via a 
rotating valve system and is pushed through the column by solvents. The column sits in a 
thermostatted temperature compartment, the sample components interact with stationary phase 
inside the column and are separated based on their affinity to the stationary phase. From the column 
the sample components go to the detector, for example the mass analyser or UV and signals 
obtained are delivered to the computer for data analysis (Agilent 2016).    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Basic overlook of mass spectrometer instrument. Sample is ionized in the 
ionisation source. Ions are separated in mass analyser according to their mass-to-charge 
ratio. Ions that emerge from the mass analyser are measured in the detector that converts 
the ions into electrical signals. The computer processes the electrical signals from the 
detector, data is produced. The system works under vacuum to allow ions to reach the 
detector, prevent ion collisions with other molecules (Cooper 2013). 
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The first step in MS is the production of gaseous ions of the compound. Ions are produced 
in the ionisation source. There are variety of ion sources, which can be utilised depending 
on the physico-chemical properties of analyte and the energy required during the ionisation 
process (Hoffmann 2007). Some ionisation techniques are soft, and transfer minimum 
energy during ionisation, while other techniques are highly energetic and cause extensive 
fragmentation of the drug (Hoffmann 2007).  A common ionisation technique utilised in 
forensic toxicology is electrospray Ionisation (ESI). ESI is a soft ionisation technique that 
works under atmospheric pressure and can easily be coupled to a LC system (Hoffmann 
2007). The sample from the LC comes to the ESI source through a thin needle. As the 
sample is constantly sprayed a high electrical potential is applied to the needle, resulting in 
the formation of highly charged droplets. These droplets are driven electrically and the 
solvent molecules in the sample are vaporised with aid of warm neutral gas, usually 
nitrogen.  As the solvent contained in droplets is evaporated it causes them to shrink and 
their charge per unit volume to increase. There are three theories what happens afterwards, 
ion evaporation theory, charge residue theory and the chain ejection model. Ion evaporation 
theory states that as the droplet is decreasing in volume and is increasing in charge the 
repulsive forces (coulomb forces) increase. These forces will eventually exceed the surface 
tension of the solvent, causing what is known as the coulomb explosion, resulting in ions 
desorbing into the gas phase. The evaporation theory is associated with low molecular 
weight analytes (Konermann et al. 2013), while the charge residue model is thought to apply 
for large molecular weight analytes, such as proteins. The evaporation theory involves 
suggest that the solvent is evaporated and as the last solvent shell evaporates the charge 
of the vanishing droplet is transferred to the compound (Konermann et al. 2013).  In the 
chain ejection model, which typically occurs for unfolded proteins, as the solvent is 
evaporated the chains of protein migrate to the solvent surface. Afterwards one chain 
terminus gets expelled into the vapor phase, which is followed by step wise ejection of 
remaining protein chains (Konermann et al. 2013). These models apply in both positive and 
negative ionisation modes (Konermann et al. 2013). The purpose of the ionisation step is 
to produce high enough energy to knock an electron off the drug molecule to form a 
positive ion. This ion is called the molecular ion or sometimes the precursor/parent ion. 
Once a sample has cleared the ionisation stage it then enters the vacuum of the mass 
spectrometer wherein it is analysed for molecular weight and fragmentation pattern. The 
mass analyser is the section of the mass spectrometer where the ions are separated based 
on their mass-to-charge ratio. There is a variety of mass analysers, all of which use 
magnetic and electric fields to achieve separation. Mass analysers can be combined for 
better results and multiple experiments. A common mass analyser system used is the triple-
quadrupole (QqQ), this is a hybrid system consisting of three quadrupole mass analysers. 
QqQ is a tandem system, as the analysis is performed in different mass analysers. QqQ 
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system can be broadly separated into three stages Q1, Q2 and Q3. In Q1, the parent ions 
are identified. Q1 filters the parent using the stability of the trajectories in oscillating electric 
fields to separate ions according to their mass-to-charge ratio (Hoffmann, 2007).  Q1 is 
composed of four parallel electrical rods with varying direct current and alternating radio-
frequency potentials. Ions formed in the ionisation source are pulsed towards the Q1 by an 
electric field. A positive ion will move in the direction of a negatively charged rod. If the 
potential is changed the ion will switch is movement path before striking the rod. If this 
occurs, they undergo oscillation (trajectory) and only ions with specific mass-to-charge 
range will survive the path to the collision cell (Q2).  (Hoffmann 2007). Q2 consists of 
quadrupoles operating in only radio frequency (RF) mode and are used for focusing ions as 
collision cells. It is in this portion of the mass spectrometer, Q2, that ion fragmentation 
occurs and daughter ions are produced. Inside Q2 an ion collision with an inert gas (helium 
or nitrogen) occurs. This process is called collisionally activated dissociation (CAD) or 
collision-induced dissociation (CID). The result is the production of product (daughter) ions 
from the ions selected from first quadrupole, (precursor/parent ions). From the collision cell 
ions migrate to the last quadruple (Q3), where they are filtered and sent to the detector for 
quantitative analysis. (El-Aneed et al. 2009). The detector measures the current produced 
by the ions, a current which is then converted into a digital value and sent to the computer 
the system. 
1.6.1 SC and natural cannabinoids analysis 
The analysis of SC presents various challenges there are over 160 SC drugs in circulation, 
with a multitude of chemical structures (EMCDDA 2017a). Analytical methods need to be 
developed and constantly updated to keep up with the ever changing structures of the new 
analogues, for forensic toxicology laboratories this is time consuming and costly. In addition, 
the reference materials are not always available, are expensive and in many cases non-
existent for the latest SC compounds (Favretto et al. 2013). For the new generation of SC 
a conventional method like LC-MS/MS is not always possible (Favretto et al. 2013).  As new 
compounds have no reference materials and no defined fragmentation patterns frequently 
LC with high resolution mass spectrometry is needed to detect compounds based on their 
accurate mass (Aldlgan and Torrance 2016, Favretto et al. 2013). The detection window for 
compounds in blood for SC can be as short as 2-3 hours (Aldlgan and Torrance 2016). As 
a result there is a requirement for highly sensitive methods as these drugs are usually 
present at low concentrations in human matrices and frequently detected in blood in 
concentrations below 1ng/mL (Langford and Bolton 2018, Rojek et al. 2017). The stability 
of SC in biological matrices is also not known (Langford and Bolton 2018). Research to date 
has suggested that frequently no parent compounds are present in urine samples of SC 
users (Favretto et al. 2013). This coupled with no reliable knowledge of the metabolites 
results in many samples that might have SC present producing false negatives. Moreover, 
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some SC have similar metabolites, which poses problems for interpretation of the analytical 
data (Presley et al. 2016). Therefore, due to the cost, the required sensitivity of the methods, 
difficulty of obtaining reference materials and the supposed infrequent use of SC, they are 
frequently not part of the routine toxicological testing panel in numerous forensic toxicology 
laboratories in the UK. 
Depending on sensitivity requirements different methods may be utilised, with MS based 
methods being the more sensitive (Citti et al. 2018). Screening analysis is usually carried 
out by gas chromatography with mass spectrometry (GC-MS) or LC-MS/MS, with latter 
being more sensitive and then used for quantitative analysis with additional ion transitions 
used to confirm the presence of the drug. The method of choice for analysis of cannabinoids 
in recent years has become LC-MS/MS (Citti et al. 2018). 
 
1.7 Method development and validation 
Method development for LC-MS/MS is task specific, dependent on what are the 
requirements of the customer or research that is being carried out. In general method 
development involves three processes: sample preparation, chromatography and mass 
spectrometric detection. The start of method development is the consideration of what 
analytes need to be analysed, concentration range of the analytes of interest and the matrix 
that will be analysed (Polettini 2006) Once the mentioned parameters are known, literature 
search about the analyte, previous methods should be carried out. The undertaken research 
helps to find out what are the best starting conditions for MS, what column to use for analysis 
and to select most efficient sample preparation technique. The first experiments that need 
to be carried out is the infusion of analytes into the MS. The next set of experiments is the 
development of chromatography method. Finally, a sample preparation technique needs to 
be developed. In forensic toxicology solid phase extraction (SPE) is considered the most 
reliable and sensitive technique for sample preparation and extraction (Bayne 2010).    
After a method is developed it needs to be validated to assure reliability, applicability of the 
method for the required purposes and to establish method`s limitations. In forensic 
toxicology  the governing bodies that give guidelines for method validation are: Scientific 
Working Group for Forensic Toxicology (SWGTOX), United Kingdom and Ireland 
Association of Forensic Toxicologists (UKIAFT),  international standard for testing and 
calibration laboratories (ISO 17025) and also in the UK the Forensic Science Regulator 
(Elliott et al. 2018). The parameters that need to be considered and tested based on 
governing body guidelines are: accuracy (bias), precision, carryover, selectivity and 
specificity, matrix effect (ME), limit of detection (LOD), limit of quantitation (LOQ), linearity 
(calibration model), range, recovery (RE), reproducibility, repeatability, ruggedness, stability 
and dilution integrity. The general definitions for these parameters are presented in Table 
4. Prior to starting any experiments, a validation plan needs to be created (SWGTOX 2013). 
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The plan sets out criteria for each parameter, experiments that will be performed and limits 
of the method to allow it to fit for use. All the experiments need to be carried out in the 
matrix, for which the method is intended to be used (SWGTOX 2013, Polettini 2006). In 
addition, some minimum criteria for parameters is set by UKIAFT, SWGTOX and ISO 
17025. Moreover, criteria is set for methods, that are employed for analysis of samples 
related to Road Traffic Act 1988 Section 5A, by Forensic Science Regulator in FSR-C-133 
(Forensic Science Regulator 2020).  
Table 4: General definitions of parameters that need to be tested for method validation (SWGTOX 
2013) 
Parameter Definition 
Accuracy (Bias) Measurement of closeness of the calculated value for the 
measurand and to the true value of a measurand. 
Precision The closeness of agreement of repeated measurements from 
multiple samples of same homogenous sample. 
Linearity (calibration 
model) 
A mathematical model that demonstrates relationship between 
the analyte signal and its concentration. 
Range The concentration that can be adequately determined. 
Carryover The appearance of analyte signal in a subsequent sample after 
analysis of positive sample. 
Matrix effect Suppression or enhancement of analyte signal due to 
interferences from the matrix. 
LOD The lowest concentration of the analyte that can be reliably 
differentiated from background noise. 
LOQ The lowest concentration that can be reliably measured. 
Selectivity and 
specificity 
The ability to detect, differentiate the analyte of interest, when 
there are other non-targeted analytes present, other drugs, 
impurities. 
Recovery The percentage of analyte response after sample preparation 
compared to solution of neat analyte of same concentration. 
Ruggedness The susceptibility of a method to small changes that might 
occur during day to day analysis, for example small 
temperature or pH variations. 
Reproducibility The preparation of samples by more than one analyst on 
separate days in same laboratory. 
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Table 4: (Continued) 
Parameter Definition 
Repeatability Testing the sample on different days to test the closeness of 
the values to one another on different days. 
Dilution integrity Testing the sample accuracy when using smaller volumes of 
sample than in the method. 
Stability Testing the variability of sample concentration when they are 
kept frozen, are not analysed on same day when they are 
prepared. 
 
1.8 Aim and objectives of the project 
Currently there is a lack of methods that analyse both natural and synthetic cannabinoids. 
Therefore, the aim of the research is to develop and validate a method that can quantify 
natural cannabinoids, THC and THC-COOH and several synthetic cannabinoids in a single 
run using LC-MS/MS. 
The research objectives:  
• Assess matrix effects utilising the techniques recommended by Matuszewski et al. 
(2003). 
• Develop and validate method suitable for analysis of JWH-018, one metabolite of 
JWH-018, AM-2201, AB-CHMINACA. These SC have been chosen as they have 
reliable reference materials and are among the most commonly abused SC in the 
UK 
• Validate the method based on the requirements of SWGTOX, UKIAFT and ISO 
17025 standards.  
• Develop and validate a method that meets the quality guidelines of road traffic 
toxicology casework samples in the UK. 
• Develop and validate a method with sensitivity parameters that will allow effective 
detection of SC in real world samples. 
• Perform robustness testing on the quantitation of THC samples in blood under 
conditions of dilutions and physiological changes to the sample matrix due to blood 
coagulation. 
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2. Methods and materials 
2.1 Reagents and chemicals 
The following reagents and chemicals were utilised in this project: liquid chromatography 
mass spectrometry (LC-MS) grade acetonitrile (ACN) (Fisher Scientific, Loughborough, 
UK), LC-MS grade water (Fisher Scientific), formic acid (Sigma Aldrich, Gillingham, UK), 
acetic acid (Fisher Scientific), defibrinated horse blood (TCS bioscience, Buckingham, UK), 
distilled water, LC grade methanol (MeOH) (Fisher Scientific), hexane (Fisher Scientific), 
ethyl acetate (Fisher Scientific), sodium acetate (Sigma Aldrich), sodium hydroxide (NaOH) 
solution (Fisher Scientific), hydrochloric acid (HCl) (Fisher Scientific) and potassium 
dihydrogen orthophosphate (Fisher Scientific). 
The following Cerilliant (Gillingham, UK) solutions were used for calibration curve: THC 1.0 
mg/mL, THC-COOH 100µg/mL, THC-COOH-D3 100 µg/mL, THC-D3 100µg/mL, JWH-018 
100µg/mL, AB-CHMINACA 100µg/mL, “Spice Cannabinoid Mix 2” 100µg/mL, JWH-018 N4-
hydroxypentyl 100µg/mL and JWH-018 N4-hydroxypentyl-D5 100µg/mL. Cayman 
chemicals (Michigan, USA) solution AM-2201-D5 5.0mg/mL was used for calibration curve. 
LGC (Teddington, UK) solution THC-COOH 100µg/mL was used for quality control (QC) 
samples. Sigma Aldrich solution THC 1.0mg/mL was used for QC samples. 
Strata C18-E (55 µm, 70 A) 200 mg/3 mL cartridges from Phenomenex (Macclesfield, UK) 
were used for extraction procedure. 15mL conical centrifuge tubes from Fisher Scientific 
were employed for sample preparation. 5mL LABCO (Lampeter, UK) vials with 1% sodium 
fluoride/potassium oxalate were utilised for collection of whole blood. 6mL Vacutest 
(Arzergrande, ITL) clot activator tubes were utilised for collection of whole blood for clotting. 
 
2.2 Reagent preparation 
The following reagents were made and used for sample extraction and preparation. 
2.2.1 Internal standard solution  
To a 2.5mL volumetric flask the following solutions were added THC-COOH-D3 100µg/mL 
(125µL),  THC-D3 100µg/mL (25µL), AM-2201-D5 (100µL) (after diluting 5µL of the original 
AM-2201-D5 5.0mg/mL  solution in 995µL of MeOH), JWH-018 N4-hydroxypentyl-D5 
100µg/mL (25µL) and made up to the volume with MeOH, to get working solution e. 
2.2.2 Solution for calibrators  
To a 2.5mL volumetric flask the following solutions were added THC 1.0mg/mL (5µL), THC-
COOH 100µg/mL (250µL), JWH-018 100µg/mL (25µL), “Spice Cannabinoid Mix 2” 
100µg/mL (25µL), AB-CHMINACA 100µg/mL (25µL), JWH-018 N4-hydroxypentyl 
100µg/mL (25µL) and  made up to volume with MeOH to get working solution a (WSA). 
100µL of WSA was added to a 1mL volumetric flask and made up to the volume with MeOH 
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to get working solution b (WSB). 100µL of WSB was added to a 1mL volumetric flask and 
made up to the volume with MeOH and labeled as working solution c (WSC). 
2.2.3 Solution for QC 
To a 5mL volumetric flask the following solutions were added THC 1.0mg/mL (5µL), THC-
COOH 100µg/mL (250µL), JWH-018 100µg/mL (25µL), “Spice Cannabinoid Mix 2” 
100µg/mL (25µL), AB-CHMINACA 100µg/mL (25µL), JWH-018 N4-hydroxypentyl 
100µg/mL (25µL) and made up to the mark with  MeOH, this solution was labelled as 
working solution d (WSD). 50µL of WSD was added to 200µL of MeOH in a 1mL volumetric 
flask and labelled as working solution f (WSF). 
2.2.4 2M sodium acetate buffer (pH 4) 
Distilled water (80mL) was added in a 0.1L volumetric flask to which sodium acetate (4.9g) 
and acetic acid (14.07mL) was added. The buffer was adjusted to final desired pH using 
HCl or NaOH. The solution was made up to the volume.   
2.2.5 0.1M hydrochloric acid 
To a 0.1L volumetric flask 4M HCl (2.5mL) was added and made up to the volume with 
distilled water. 
2.2.6 0.1M phosphate buffer (pH 7) 
Potassium dihydrogen orthophosphate (13.61g) was dissolved in distilled water (900mL). 
The pH was adjusted to pH 7.0 with NaOH or HCl and made up to 1L using distilled water. 
2.2.7 Elution mixture 
To a 20mL volumetric flask hexane (14mL) and ethyl acetate (6mL) was added. The ratio 
of hexane to ethyl acetate was 7:3 in the mixture. 
 
2.3 Preparation of calibration line and QC samples  
Table 5 outlines the volumes of working solutions utilised to prepare calibration curve and 
QC samples in blood matrix. 
Table 5: Volumes of working solutions used for calibrators and QC to spike blood for extraction 
Calibrator/QC Volume Solution 
to use 
Concentration 
THC/THC-
COOH/SC (ng/µL) 
Final 
volume 
Final 
Concentration 
THC/THC-
COOH/SC 
(ng/µL) 
Cal 1 50µL WSC 0.01/0.05/0.005 1mL 0.5/2.5/0.25 
Cal 2 10µL WSB 0.1/0.5/0.05 1mL 1/5/0.5 
Cal 3 40µL WSB 0.1/0.5/0.05 1mL 4/20/2 
Cal 4 10µL WSA 1/5/0.5 1mL 10/50/5 
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Table 5: (Continued) 
Calibrator/QC Volume Solution 
to use 
Concentration 
THC/THC-
COOH/SC (ng/µL) 
Final 
volume 
Final 
Concentration 
THC/THC-
COOH/SC 
(ng/µL) 
Cal 5 20µL WSA 1/5/0.5 1mL 20/100/10 
QC1 (low) 20µL WSF 0.1/0.5/0.05 1mL 2/10/1 
QC2 (high) 30µL WSD 0.5/2.5/0.25 1mL 15/75/7.5 
 
2.4 Sample preparation and extraction 
2.4.1 Sample preparation 
Samples, calibrators, blanks and QC standards had a starting volume of 1mL of whole blood 
in 15mL conical centrifuge tubes. It should be noted that, later experiments indicated that 
the sample volume can be reduced to 0.5mL. Internal standard (10ng/mL, 50ng/mL and 
7.5ng/mL for THC, THC-COOH and SC respectively) was added to all samples, calibrators 
and QC, and vortexed thoroughly for ≈10s. Following this ACN (2mL) was added to all 
samples, calibrators, blanks and QCs, and vortexed for ≈10s, and centrifuged at 3500g at 
20°C for 15 minutes. The supernatants were transferred to a new 15mL conical centrifuge 
tubes and diluted with 2M sodium acetate buffer (pH 4) (1mL) and vortexed for ≈10s. After 
sample preparation SPE extraction was performed as described below. 
2.4.2 SPE extraction 
The extraction process selected was the SPE method which was adapted from Aizpurua-
Olaizola et al. (2017). SPE was selected as it achieves highest sensitivity, robustness of the 
extraction methods used in forensic toxicology. An additional vacuum step was added, after 
the wash steps to the method, to remove the matrix interferences, have a cleaner sample 
that will not overload column with interfering substances. Buffering solutions were tested to 
optimise SPE extraction. The solutions were tested in blood matrix in duplicates. 
The SPE procedure was utilizing strata C18-E (55 µm, 70 A) 200 mg/3 mL cartridges. The 
cartridge was conditioned by sequential elution of: methanol (3mL), water (3mL), 0.1M 
phosphate buffer pH 7 (1mL). Afterwards the samples were applied to appropriate 
cartridges. The column was washed sequentially with water (2mL), 0.1M hydrochloric acid 
(2mL), methanol (200µL). The cartridges were dried under vacuum for five minutes. The 
elution solvent (hexane/ethyl acetate mixture) (1.5mL) was applied to each column and 
collected into LC vials. The eluted solvent was evaporated under nitrogen flow at 40°C. 
Samples were reconstituted in 160µL of 50/50 of mobile phase A (water 0.1% formic acid) 
and mobile phase B (ACN 0.1% formic acid) and vortexed for ≈20s. 
37 
 
2.5 Preparation of clotted blood samples 
The study protocol was approved by The Faculty Research Ethics Committee (FREC) of 
Kingston University London, Ethics code: 1819063.1. Venous blood was taken from one 
male participant from the antecubital vein into 5mL LABCO vials and into 6mL Vacutest clot 
activator vials. Twenty clotted samples were made and ten whole venous blood samples 
that were used as a control for the variability of spiking, extraction. Both vials were spiked 
2-3 minutes after blood collection (before blood clots in clot activator vials) with the same 
concentrations of analytes, vortexed and kept to homogenise for one hour in 4°C in 
refrigerator. Afterwards the samples were extracted and analysed as duplicates with a 
calibration line and QC samples alongside it. All QC samples passed the required criteria. 
Once sample analysis was complete samples were destroyed as per HTA guidelines. 
 
2.6 Method validation experiments 
2.6.1 Accuracy (bias) 
Accuracy was assessed by using QC results obtained from repeatability and reproducibility 
batches, containing QC samples at two levels, low and high with two replicates. Five runs 
were examined in total. The accuracy was determined as a percentage by comparing the 
calculated value to the expected concentration. Accuracy for natural cannabinoids should 
not exceed 20%, as it is the minimum requirement proposed by FSR-C-133 (Forensic 
Science Regulator 2020). The accuracy for synthetic cannabinoids should not exceed 30%, 
as this is the common percentage utilised by other researchers (Borg et al. 2017, Freijo et 
al. 2014, Kneisel et al. 2013).   
2.6.2 Precision 
Precision was assessed using the QC results obtained from repeatability and reproducibility 
batches. Five different runs were looked at containing QC samples at 2 levels low and high 
with 2 replicates. Coefficient of variance (%CV) value was looked within run and within days. 
The within day precision was calculated by finding the standard deviation of duplicates, 
dividing it by the mean value and multiplying by 100. The between day precision was 
calculated by looking at all values for the QC (n=10), finding the standard deviation for them, 
dividing it by the mean of QC (n=10) and multiplying by 100. The precision for all analytes 
should not exceed 20% (SWGTOX 2013). 
2.6.3 Linearity (calibration model) 
Linearity was demonstrated by running a five point calibration curve five times. The 
concentrations for THC was in the range of 0.5-20ng/mL (0.5, 1, 4, 10 and 20ng/mL), 
concentrations for THC-COOH was 2.5-100ng/mL, (2.5, 5, 20, 50 and 100ng/mL), 
concentration for AM-2201, JWH-018,  AB-CHMINACA, JWH-018 N4-hydroxypentyl 0.25-
10ng/mL (0.25, 0.5, 2, 5 and 10ng/mL)  to cover the expected working range of the analysis. 
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For linearity to pass the R2 must be equal or greater than 0.99, as recommended by 
SWGTOX, UKIAFT and ISO 17025. 
2.6.4 Range 
For THC 5-20ng/mL, for THC-COOH 2.5-100ng/mL and for all SC 0.25-10ng/mL was the 
chosen range of the method. QC samples were run at concentrations covering the range of 
calibration curve to demonstrate acceptable accuracy and precision at low and high 
concentrations. The QC values had to achieve desired accuracy and precision for the 
analytes for the parameter to pass. 
2.6.5 Carryover 
Blank matrix samples were analysed immediately after the highest calibrator. The area 
counts in blank matrix sample was required to be less than 25% of the area counts of the 
lowest calibrator to be accepted free of carryover. However, if the area was above 25% it 
was expected that then ion ratio for the analyte fails for there not to be carryover (SWGTOX 
2013).  
2.6.6 LOD 
Blank matrix spiked with analytes at (THC 0.25ng/mL, THC-COOH 1.25ng/mL, AM-2201, 
JWH-018, AB-CHMINACA, JWH-018 N4-hydroxypentyl 0.125ng/mL) was analysed 
alongside the calibration curve and QCs samples. The LOD was the lowest concentration 
at which the S/N ratio is greater or equal to 3:1 and achieves identification criteria (retention 
time, mass spectral ion ratios based on calibration curve of the run) (SWGTOX 2013). 
2.6.7 LOQ 
The LOQ for the analytes was the lowest calibrator. For LOQ it was expected that no 
significant difference between calculated value and expected value will be found and signal 
to noise ratio will be above or equal to 10:1. Also, the identification criteria (retention time, 
mass spectral ion ratios based on calibration curve of the run) had to be met. 
2.6.8 Selectivity and specificity 
Selectivity and specificity was tested by making independent solution containing analytes 
of interest, their internal standards and common drugs of abuse found in blood: alcohol, 
cocaine, diazepam and benzoylecgonine. Analytes were expected to meet the criteria of 
identification (retention time, mass spectral ion ratio based on calibration curve),  
Also, a solution of blank blood with no analytes was analysed. Carryover criteria had to pass 
for this parameter to be valid. 
2.6.9 Repeatability 
A sample was spiked with analytes and analysed on two different occasions, alongside the 
calibration curves. No significant difference was expected to be found for the concentrations 
and the difference should not be more than 20%. 
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2.6.10 Reproducibility  
This was assessed by preparing three batches on three different days by three different 
analysts but run on the same instrument, as recommended by FSR-C-133 and ISO 17025. 
Each batch contained a calibration curve consisting of five points and QC`s at two different 
concentrations. The QC samples had to pass. 
2.6.11 Ruggedness 
Results from different analysts was looked at. Different pH buffers (made on different days, 
by different people) was tested. Mass spectrometry source plate was cleaned before 
analysis, temperature change in the room and its effect on analysis monitored. Day to day 
variability should not affect the assay accuracy.  
2.6.12 Matrix effect  
The matrix effect was analysed based on Matuszewski et al. (2003) recommendation. Post 
extraction addition approach was used in which two sets of samples were compared. Set 
1(A) consisted of samples spiked with analytes and their internal standards in 1mL of LC-
MS grade methanol and afterwards reconstituted. Set 2(B) consisted of samples spiked 
with analytes and their internal standards before the evaporation of the elution solution 
following extraction of blank blood. The ion suppression or enhancement was established 
at low and high concentrations. Formula for calculating matrix effect was: ME%=(B/Ax100)-
100. The values for ME should not exceed 25%, however if the values did exceed 25% an 
impact on LOD, LOQ and bias was looked and evaluated, to see if all 3 values are suitable, 
pass their required criteria. 
2.6.13 Recovery  
Recovery was established based on recommendations from Matuszewski et al. (2003). Pre 
spiked and neat sample sets were compared. Set 1(A) consisted of samples spiked with 
analytes and their internal standards in 1mL of LC-MS grade methanol and afterwards 
reconstituted. Set 3 (C) consisted of blank blood samples spiked with analytes and their 
internal standards followed by extraction procedure. Recovery was established at low and 
high concentrations. The formula for calculating recovery was: RE%=C/Ax100. It was 
expected that the recovery will be above 80% if not it should not affect the bias and LOQs. 
2.6.14 Stability 
Stability was tested by analysing the same blood sample, spiked with analytes, on two 
different occasions, on day one and then after a week (condition 1). The blood sample 
concentrations were expected to be similar on both days when analysed (not different by 
more than 20%). 
Stability was also tested by extracting samples and keeping them in the refrigerator (4°C) 
for two weeks (condition 2). The extracted samples after being kept in the refrigerator were 
expected to pass bias and linearity criteria. 
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2.6.15 Dilution Integrity 
Sample dilution of 1:2 was tested. Into 0.5mL of fortified blood 0.5mL of blank blood was 
added to dilute it by 1:2.  Sample afterwards was spiked with internal standard and standard 
procedure for extraction was followed (method 1 of dilution). Also, dilution integrity was 
tested by extracting only 0.5mL of fortified blood instead of 1mL (method 2 of dilution). 
Samples bias was expected not exceed 20% from the expected values, identification criteria 
to be achieved (retention time, ion ratios, based on the calibration curve of the run). 
 
2.7 Instruments and laboratory equipment 
LC used was Agilent (Cheshire, UK) 1260 Infinity Binary Pump. MS used was Agilent Triple 
Quad LC/MS 6430. Two columns were employed for method analysis Agilent 
InfinityLabPoroshell 120 EC-C18 2.1 x 75 mm, 2.7 µm, narrow bore LC column (Agilent 
2013) and Phenomenex Kinetex 2.6 µm polar C18 100A, 150 x 3.0mm column. Pipettes 
utilised were VWR (Lutterworth, UK) positive displacement pipette 1 -10 μL, VWR positive 
displacement pipette 10 -100 μL and VWR positive displacement pipette 100 -1000 μL. 
 
2.8 Instrument parameters 
The parameters for ion source were: positive electrospray, gas temperature at 350°C, gas 
flow at 12L/min, nebulizer 25psi, capillary +4000 voltage(V) and EMV+ 400. 
The parameters for LC were: mobile phase A water 0.1% formic acid, mobile phase B ACN 
0.1% formic acid, temperature 20°C, stop time for LC pump 10.6 min, injection with needle 
wash (ACN as wash solvent), injection volume 20µl, injection draw position -1.6mm, 
injection draw speed and eject speed 200µl/min and auto sampler temperature 20°C. The 
gradient utilised for the method is described in Table 6. 
Table 6: LC Gradient Elution Method Parameters 
Time (min) Mobile Phase 
A (%) 
Mobile Phase 
B (%) 
Flow 
rate 
(mL/min) 
Max 
pressure 
(bar) 
0 60 40 0.35 500 
1 60 40 0.35 500 
2.5 10 90 0.35 500 
8 10 90 0.35 500 
8.5 60 40 0.35 500 
10.5 60 40 0.35 500 
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3. Results 
3.1 Method development 
3.1.1 Infusion 
Post column infusion with a syringe pump at the speed of 20µL/min and MassHunter 
Optimiser software were used to construct the analyte database. The settings for the ion 
source were the same for all analytes, as described in the method section 2.7. All analytes 
were infused individually with the optimiser software settings as described in Table 7. All 
samples were made in 50:50 (mobile phase A, water 0.1% formic acid and mobile phase B, 
ACN 0.1% formic acid mix) for infusion with a concentration of 50ng/mL for all compounds. 
During the infusion a continuous flow of solvent is pumped into the ion source. The optimiser 
software identifies the parent ion and the optimum fragmentor energy and collision energy 
for the parent ion to target and quantifier ion transitions. The results of all compounds 
precursor ions and product ions, energies are presented in Table 8. 
 
Table 7: Optimiser parameters used for infusion of natural and synthetic cannabinoids 
Parameter Value 
Optimisation dwell 
time 
20ms 
Fragmentor course 
range 
60-180V 
Collision energy 
range 
10-70V 
Low mass cut-off 50m/z 
 
Table 8: Dynamic multiple reaction monitoring (dMRM) transitions of natural and synthetic 
cannabinoids. 
Analyte name 
Precursor 
ion (amu) 
Retention 
time 
(min) 
Retention 
time 
window 
(min) 
Fragmentor 
(V) 
Product 
ions 
(amu) 
Collision 
energy 
(V) 
Dwell 
time 
(ms) 
THC 315.2 6.340 1.19 84 
193.2 
123.0 
259.2 
21 
32 
18 
78.64 
78.64 
78.64 
THC-D3 318.2 6.367 1.19 122 196.2 21 78.64 
THC-COOH 345.2 4.960 0.94 96 
327.2 
299.2 
193.1 
13 
17 
25 
35.63 
35.63 
35.63 
 
42 
 
 
Table 8: (Continued) 
Analyte name 
Precursor 
ion (amu) 
Retention 
time 
(min) 
Retention 
time 
window 
(min) 
Fragmentor 
(V) 
Product 
ions 
(amu) 
Collision 
energy 
(V) 
Dwell 
time 
(ms) 
THC-COOH-
D3 
348.2 4.940 1.19 76 330.2 12 40.52 
JWH-018 342.2 5.580 1.01 94 
155.1 
214.2 
127.0 
21 
24 
44 
49.40 
49.40 
49.40 
AM-2201 360.2 4.960 0.97 122 
155.1 
127.1 
232.2 
26 
54 
22 
37.45 
37.45 
37.45 
AM-2201-D5 365.2 4.950 0.96 122 155.0 25 35.63 
AB-
CHMINACA 
357.2 4.480 1.17 98 
241.3 
312.4 
340.3 
26 
14 
10 
46.19 
46.19 
46.19 
JWH-018 N4-
hydroxypentyl 
358.2 4.390 1.19 122 
155.1 
127.1 
22 
54 
62.10 
62.10 
JWH-018 N4-
hydroxypentyl- 
D5 
363.2 4.370 1.15 98 155.0 22 
 
69.57 
Amu - atomic mass unit, in bold the quantifier ion 
 
3.1.2 LC gradient development 
The development of the LC method was based on a literature search of methods that 
previously analysed cannabinoids. At the beginning of method development Kinetex polar 
C18 column was selected as well as the solvents to be used, water 0.1% formic acid and 
ACN 0.1% formic acid, initial conditions for the gradient (Table 9). A method was developed 
that could detect THC and THC-COOH for the column, with the prospect of adding SC at a 
later stage the method development and validation process. Calibration and with QCs 
samples were run on the Kinetex polar C18 column for THC and THC-COOH. Both 
calibration lines and QCs run on the column passed their required criteria. However, it later 
emerged that repeated experiments and analysis of sample extracts led to a significant 
decline in the column’s performance. This resulted in instability in the retention time of THC 
and THC-COOH and a corresponding loss of sensitivity due poor analyte resolution. 
Modifications of the chromatography and extension of the gradient runtime by 10 minutes 
were carried out. These alterations indicated that the analytes shifted by six minutes to the 
right and changed the order in which they were eluting. Moreover, the sensitivity for the 
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analytes decreased as well, previously 0.5ng/mL of THC could be detected, but after the 
column problem the lowest concentration that could be quantified was approximately 
2ng/mL. The data relating to these method development experiments is detailed in the 
appendices (Column issue section).  Due to the issues another column was selected Agilent 
InfinityLabPoroshell 120 EC-C18, this was utilised with same solvents and gradient (Table 
9). Initial conditions for the method were not achieving separation, THC was not eluting 
during the run, only THC-COOH peak was detected. The gradient was changed from 70% 
B to 90% B and the run extended to 13 minutes. The new gradient achieved adequate 
separation for the compounds. Later the run time was optimised. The final method chosen 
is described in method section 2.7 (Table 6). 
 
Table 9: Gradient of method 1, the initial method used for method development for, which did not 
elute THC in the run 
Time (min) Mobile 
Phase A (%) 
Mobile phase 
B (%) 
Flow rate 
(mL/min) 
Max pressure 
(bar) 
0 60 40 0.35 500 
1 60 40 0.35 500 
2.5 30 70 0.35 500 
9 30 70 0.35 500 
9.5 60 40 0.35 500 
11 60 40 0.35 500 
 
3.1.3 LC and MS optimisation 
Once an acceptable gradient was found the method was optimised to achieve good 
sensitivity, robustness. 
3.1.3.1 Ion source parameters 
Optimisation of the ion source was carried out by testing different flow rates and nebulizer 
pressures, which have an influence on response sensitivity (Table 10). The results indicated 
that the initial conditions selected for infusion, should be used (underlined parameters), as 
these parameters achieved best signal to noise ratio for the analytes. 
3.1.3.2 Injection volume 
The injection volume of 20µL was chosen to achieve the required sensitivity of below 
1ng/mL. 
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Table 10: Different ion source parameters and their effect on response of the analytes 
Underlined text denotes the parameters that were most sensitive and chosen for the method 
 
3.1.3.3 Ion scan type  
dMRM scan type was selected, as this enables the software to optimise and select dwell 
times for each ion, thereby achieving a higher sensitivity. 
3.1.3.4 Reconstitution solvent 
Different reconstitution volumes for samples were tested (Figure 15). A volume of 160µL 
was chosen, as it achieved better results than higher volumes and allowed sufficient sample 
volume for a reinjection. 
Multiple reconstitute solvents were tested (Figure 16). A 50:50 mix of mobile phase A (water 
0.1% formic acid) and mobile phase B (ACN 0.1%formic acid) was chosen, as it achieved 
higher sensitivity (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters tested for the 
ion source 
THC signal to noise 
ratio (2ng/mL sample) 
THC-COOH signal to 
noise ratio (10ng/mL 
sample) 
Nebulizer 25psi, flow 12L/min 488.6 150.8 
Nebulizer 40psi, flow 12L/min 420.6 135.2 
Nebulizer 40psi and flow 
10L/min 
320.2 101.5 
THC  
THC-COOH  
THC  
THC -
COOH 
Figure 15: Different reconstitute volumes for same concentration sample, upper 
200µL, lower 160µL. With the lower reconstitute volume, higher response for the 
analytes was achieved.  
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3.1.4 Extraction optimisation 
Experiments were carried out to optimise extraction (Table 11). Different buffering solutions 
were tested in blood matrix in duplicates. The recovery percentage was calculated based 
on Matuszewski et al. (2003). The final method chosen was with pH4 and pH7 buffering 
conditions in place of pH4 and pH3 buffers described by Aizpurua-Olaizola et al. (2017). 
The pH4 and pH7 buffering conditions were chosen as they achieved the highest recovery 
percentages for THC and THC-COOH. It should be noted that these experiments were 
carried out only with THC and THC-COOH in the matrix, therefore the final recovery was 
different, when more analytes were present in the matrix. 
Table 11: Extraction experiment results for THC and THC-COOH 
Preparation method 
THC 
recovery (%) 
THC-COOH 
recovery (%) 
Sample diluted with pH 4, buffer used pH3, first wash 
HCl then with water 
58.77 36.91 
Sample diluted with pH 4, buffer used pH7, 102.76 51.11 
Sample diluted with pH 7, buffer used pH7, 151.08 23.80 
Sample diluted with pH 4, buffer used pH3 (original 
method from the paper) 
166.16 25.17 
  Underlined text denotes the parameters that were chosen, achieved best results 
 
THC quantifier ion 
THC quantifier ion 
Figure 16: Different reconstitute solvents test. Upper result is for 50:50 of mobile 
phase A and B at 160µL volume, bottom one is mobile phase A at 160µLvolume. 
The results clearly show that using A:B mix for reconstitution is the better option, 
as it achieves higher response. 
46 
 
3.2 Method validation results 
The summarised validation results are presented in Table 12. 
Table 12: Summary of method validation results 
Criteria Result 
Accuracy All analytes with the exception of JWH-018 
passed required criteria. 
Precision All analytes with the exception of JWH-018 
passed the required criteria. 
Linearity (Calibration model) R2 was above 0.99 for all analytes.  
Range All analytes passed the required criteria. 
Carryover No carryover was observed after the highest 
calibrator for any of the analytes. 
LOD THC, THC-COOH and AB-CHMINACA 
LOD=LOQ. 
JWH-018, AM-2201 and JWH-018 N4-
hydroxypentyl LOD=0.125ng/mL. 
LOQ All LOQs, with exception JWH-018 passed. 
 
Selectivity and specificity All analytes passed the required criteria 
Repeatability All analytes passed the required criteria with 
exception of JWH-018 
Reproducibility All analytes passed the required criteria with 
exception of JWH-018 
Ruggedness All analytes passed the required criteria with 
exception of JWH-018 
Matrix effect  All analytes have matrix effect higher than 25%, 
however the LOQs, bias was not affected for all 
analytes with exception of JWH-018 
Recovery  All analytes have a recovery below 80%, 
however the LOQs, bias was not affected for all 
analytes with exception ofJWH-018 
Stability Extracted samples were stable for two weeks in 
the refrigerator and sample spiked with analytes 
and stored in the refrigerator was stable for a 
week, for all analytes with exception of JWH-018 
Dilution integrity All analytes passed the required criteria  
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3.2.1 Accuracy 
The accuracy results for QCs are presented in Table 13 and Table 14. QC1 was for THC 
2ng/mL, THC-COOH 10ng/mL, SC 1ng/mL, while QC2 was for THC 15ng/mL, THC-COOH 
75ng/mL, SC 7.5ng/mL. The accuracy of analytes, which had respective internal standards 
(THC, THC-COOH, AM-2201, JWH-018 N4-hydroxypentyl) was in the range of 20%. The 
accuracy of AB-CHMINACA, which did not have a respective internal standard was 30%. 
For JWH-018, which also did not have a respective internal standard, QCs were outside the 
30% range, however JWH-018 fail rate for QC 1 was 2 in 10, while for QC2 1 in 10. The 
method can quantify all analytes with an acceptable accuracy, with exception of JWH-018. 
 
Table 13: Accuracy results. The mean of 10 results for QC1 and QC2 
Analyte name Mean accuracy (%) QC1  Mean accuracy (%) QC2  
THC 96.94 (86.59-108.54) 94.54 (82.75-105.57) 
THC-COOH 103.75 (95.58-117.87) 97.68 (87.40-103.71) 
JWH-018 109.24 (79.18-150.9) 107.45 (84.41-132.16) 
AM-2201 101.06 (89.89-108.63) 100.13 (86.52-108.55) 
AB-CHMINACA 101.25 (78.55-112.81) 103.65 (95.03-112.03) 
JWH-018 N4-hydroxypentyl 
 
100.04 (87.16-108.79) 101.21 (92.31-108.03) 
 
Table 14: Accuracy results. Calculated concentrations range and pass rate of QC1 and QC2 in five 
calibration runs 
 
Analyte name 
Calculated 
concentration 
QC1 range 
(ng/mL) [pass 
range] 
Pass rate 
for QC1 
(%) (n=10) 
Calculated 
concentration 
QC2 range 
(ng/mL) [pass 
range] 
Pass rate 
for QC2 
(%) (n=10) 
THC 1.73-2.17 
[1.6-2.4]* 
100 12.49-15.84 
[12-18]* 
100 
THC-COOH 9.56-11.79 
[8-12]* 
100 65.55-77.79 
[60-90]* 
100 
JWH-018 0.79-1.51 
[0.7-1.3]^ 
80 6.33-9.91 
[5.25-9.75]^ 
90 
AM-2201 0.89-1.09 
[0.8-1.2]* 
100 6.49-8.14 
[6-9]* 
100 
*20% range from expected value; ^30% range from expected value 
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Table 14: (Continued) 
 
Analyte name 
Calculated 
concentration 
QC1 range 
(ng/mL) [pass 
range] 
Pass rate 
for QC1 
(%) (n=10) 
Calculated 
concentration 
QC2 range 
(ng/mL) [pass 
range] 
Pass rate 
for QC2 
(%) (n=10) 
AB-CHMINACA 0.78-1.12 
[0.7-1.3]^ 
100 7.13-8.27 
[5.25-9.75]^ 
100 
JWH-018 N4-
hydroxypentyl 
 
0.87-1.09 
[0.8-1.2]* 
100 6.92-8.10 
[6-9]* 
100 
*20% range from expected value; ^30% range from expected value 
 
3.2.2 Precision 
The results for precision experiments is presented in Table 15. The %CV value was below 
20% for all analytes with exception of JWH-018, which had %CV value above 20% but 
below 30%. The results show methods applicability to be used repeatedly for all analytes, 
with exception of JWH-018. 
Table 15: Precision results for the analytes. Within day precision, looking at five different days and 
between day, overall precision 
Analyte name 
%CV QC1 
within day 
%CV QC2 
within day 
%CV QC1 
between day 
%CV QC2 
between day 
THC 
1- 8.22 
2- 2.91 
3- 5.18 
4- 0.88 
5- 6.77 
1- 0.36 
2- 2.48 
3- 0.60 
4- 0.88 
5- 1.66 
6.08 9.50 
THC-COOH 
1-1.61 
2-1.57 
3-7.67 
4-0.19 
5-5.51 
1-1.48 
2-1.25 
3-2.92 
4-0.97 
5-1.60 
6.63 5.05 
JWH-018 
1-4.42 
2-19.50 
3-13.98 
4-25.25 
5-3.00 
1-9.70 
2-22.05 
3-8.91 
4-3.66 
5-11.08 
19.83 13.49 
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Table 15: (Continued)  
Analyte name 
%CV QC1 
within day 
%CV QC2 
within day 
%CV QC1 
between day 
%CV QC2 
between day 
AM-2201 
1-0.28 
2-0.87 
3-9.44 
4-0.40 
5-4.66 
1-1.56 
2-2.01 
3-2.90 
4-0.72 
5-1.66 
4.99 8.30 
AB-CHMINACA 
1-10.90 
2-7.18 
3-7.19 
4-8.98 
5-1.36 
1-3.50 
2-4.92 
3-1.15 
4-1.98 
5-0.89 
10.21 5.07 
JWH-018 N4-
hydroxypentyl 
1-3.02 
2-2.45 
3-9.81 
4-0.85 
5-4.43 
1-0.01 
2-1.57 
3-2.73 
4-0.46 
5-1.61 
5.59 4.77 
1,2,3,4,5 represents different days, different batches were analysed 
 
3.2.3 Linearity (Calibration model) 
Linearity results for five batches is presented in Table 16 and Figures 17-22. The method 
has passed the required linearity criteria, as R2 value was above or equal 0.99 for all of the 
analytes. The method can reliably quantify analytes, in the calibration range specific for 
analytes. 
 
Table 16: Linearity data obtained at the method validation stage  
Analyte name Linearity 
R2 day 1 
Linearity 
R2 day 2 
Linearity 
R2 day 3 
Linearity 
R2 day 4 
Linearity 
R2 day 5 
THC 0.9908 0.9967 0.9951 0.9930 0.9951 
THC-COOH 0.9962 0.9980 0.9925 0.9948 0.9925 
JWH-018 0.9907 0.9923 0.9952 0.9969 0.9952 
AM-2201 0.9965 0.9972 0.9940 0.9905 0.9940 
AB-CHMINACA 0.9978 0.9987 0.9954 0.9936 0.9954 
JWH-018 N4-
hydroxypentyl 
0.9973 0.9975 0.9948 0.9953 0.9948 
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Figure 17: Representative calibration line of JWH-018 N4-hydroxypentyl, run on 10th February 2020 
 
Figure 18: Representative calibration line of AB-CHMINACA, run on 10th February 2020 
 
 
Figure 19: Representative calibration line of THC-COOH, run on 10th February 2020 
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Figure 20: Representative calibration line of AM-2201, run on 10th February 2020 
 
Figure 21: Representative calibration line of JWH-018, run on 10th February 2020 
 
Figure 22: Representative calibration line of THC, run on 10th February 2020 
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3.2.4 Range 
All analytes with exception of JWH-018 passed the required criteria (accuracy and precision 
section), with JWH-018 having a fail rate of 2 in 10 for QC1 (low concentrations) and 1 in 
10 for QC2 (high concentrations). 
3.2.5 Carryover 
No carryover was observed for any of the analytes after the highest calibrator (Table 17). 
Table 17: Carryover after the highest calibrator was tested on three different days 
Analyte name Signal less 
than 25% of 
LOQ 
Ion ratio 
THC 
No Fail 
Yes Fail 
Yes Fail 
THC-COOH 
Yes Fail 
Yes Fail 
Yes Fail 
JWH-018 
Yes Pass 
Yes Pass 
Yes Pass 
AM-2201 
Yes Pass 
Yes Pass 
Yes Pass 
AB-CHMINACA 
Yes Fail 
Yes Fail 
Yes Fail 
JWH-018 N4-
hydroxypentyl 
Yes Fail 
Yes Fail 
Yes Fail 
 
3.2.6 LOD 
The results for LODs is presented in Table 18, it should be noted as quantitative results 
were below calibration curve the accuracy for them cannot be assured. The LODs for JWH-
018, AM-2201, JWH-018 N4-hydroxypentyl were determined to be 0.125ng/mL, as it this 
concentration signal to noise ratio, ion ratios, and retention time passed the required criteria. 
The LODs for THC, THC-COOH, AB-CHMINACA were found to be the same as LOQs, as 
it can be seen in Table 18, the ion ratios for these analytes fail at concentrations lower than 
LOQ. Figures 23-26, present the representative results, ion ratios of the LODs for analytes. 
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Table 18: LOD result summary. Three LODs were analysed 
Analyte name Accuracy 
(%) 
Signal to 
noise ratio 
Ion 
ratio 
Retention 
time (min) 
THC 
120.20 37 Fail 6.16 
119.20 35 Pass 6.22 
146.04 7 Fail 6.27 
THC-COOH 
114.64 6 Fail 4.82 
107.35 11 Fail 4.84 
114.96 11 Fail 4.89 
JWH-018 
122.48 266 Pass 5.43 
119.92 36 Pass 5.46 
96.48 160 Pass 5.51 
AM-2201 
135.44 359 Pass 4.83 
137.76 496 Pass 4.86 
130.72 231 Pass 4.89 
AB-CHMINACA 
172.08 215 Pass 4.34 
172.72 224 Fail 4.36 
168.80 384 Fail 4.41 
JWH-018 N4-
hydroxypentyl 
113.28 96 Pass  4.25 
108.88 78 Pass  4.28 
102.72 76 Pass  4.32 
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Figure 23: Representative chromatogram of LOD and ion ratios of JWH-018 N4-hydroxypentyl. The 
ion ratio for JWH-018 N4-hydroxypentyl passed, as only one ion is looked for this compound as 
qualifier (127.1), due to unreliability, instability of all other tested second qualifier ions. 
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Figure 24: Representative ion ratios for AB-CHMINACA and THC-COOH in the LOD. Both analytes 
ion ratios failed at LOD concentration. 
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Figure 25: Representative ion ratios of AM-2201 and JWH-018 in the LOD. Both analytes ion ratios 
passed at LOD concentrations 
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Figure 26: Representative ion ratio for THC in the LOD. The ion ratio failed for THC in the 
concentration of LOD 
 
3.2.7 LOQ 
All analytes passed the required criteria, with the exception of JWH-018, as for this analyte 
the accuracy was above the range of 30% (Table 19). The method for all analytes, with 
exception of JWH-018, can reliably quantify concentrations from 0.5ng/mL for THC, 
2.5ng/mL for THC-COOH and 0.25ng/mL for SC. 
 
Table 19: LOQ result summary. Three LOQs were looked at different days 
Analyte name Accuracy 
(%) 
Signal to 
noise 
ratio 
Ion ratio 
THC 
101.68 52 Pass 
117.52 12 Pass 
119.60 27 Pass 
THC-COOH 
108.59 29 Pass 
115.60 53 Pass 
110.47 22 Pass 
JWH-018 
123.00 1828 Pass 
130.52 391 Pass 
112.52 349 Pass 
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Table 19: (Continued) 
Analyte name Accuracy 
(%) 
Signal to 
noise 
ratio 
Ion ratio 
AM-2201 
107.92 571 Pass 
119.72 114 Pass 
113.16 514 Pass 
AB-CHMINACA 
120.08 1002 Pass 
112.56 190 Pass 
108.72 193 Pass 
JWH-018 N4-
hydroxypentyl 
105.40 158 Pass  
119.36 373 Pass 
112.56 195 Pass  
 
3.2.8 Selectivity and specificity 
All analytes passed their ion ratios and accuracy criteria, no additional peaks or interference 
was seen in the chromatograph from the additional compounds added (Table 20). Figure 
27 demonstrates that there were no interfering peaks present in the chromatogram for the 
sample. 
Table 20: Results for selectivity and specificity sample. The sample was spiked with analytes of 
interest and additional analytes (alcohol, cocaine and diazepam) 
Analyte name Sample concentration 
accuracy (%) 
Ion ratio 
THC 97.29 Pass 
THC-COOH 93.65 Pass 
JWH-018 103.25 Pass 
AM-2201 91.67 Pass 
AB-CHMINACA 108.76 Pass 
JWH-018 N4-
hydroxypentyl 
95.21 Pass  
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Figure 27: Selectivity and specificity sample chromatogram and concentration results. No interfering 
samples were detected, only target analytes were detected 
 
3.2.9 Repeatability 
All analytes, with exception of JWH-018, passed the repeatability criteria, showing that 
samples can be reanalysed after a week, method is reliable, can quantify analytes 
accurately (Table 21 and Table 22). 
 
Table 21: Repeatability sample values on two different days of analysis 
Analyte name Sample 
value on 
13 02 2020 
(ng/mL) 
Sample 
value on 
20 02 2020 
(ng/mL) 
Difference % 
THC 9.72 8.60 13.04 
THC-COOH 46.82 50.64 7.56 
JWH-018 5.16 3.71 38.81 
AM-2201 4.59 4.65 1.24 
AB-CHMINACA 5.43 6.10 10.96 
JWH-018 N4-
hydroxypentyl 
4.76 5.27 9.77 
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Table 22: Repeatability batches QC concentration values 
Analyte name QC1 
values on 
13 02 2020 
(ng/mL) 
QC2 values 
on 13 02 
2020 
(ng/mL) 
QC1 values 
on 20 02 
2020 
(ng/mL) 
QC2 values 
on 20 02 
2020 
(ng/mL) 
THC 1.81&2.00 
Pass 
12.56&12.41 
Pass 
2.12&2.01 
Pass 
16.20&14.51 
Pass 
THC-COOH 9.84&11.47 
Pass 
69.50&65.55 
Pass 
9.69&11.84 
Pass 
84.73&87.76 
Pass 
JWH-018 0.80&1.06 
Pass 
8.33&6.97 
Pass 
1.37&1.01 
Fail 
5.36&7.29 
Pass 
AM-2201 0.89&1.08 
Pass 
6.87&6.48 
Pass 
1.02&1.05 
Pass 
8.16&7.55 
Pass 
AB-CHMINACA 0.97&1.12 
Pass 
8.21&8.40 
Pass 
1.14&1.14 
Pass 
8.98&8.88 
Pass 
JWH-018 N4-
hydroxypentyl 
0.87&1.06 
Pass 
7.31&6.92 
Pass 
1.10&112 
Pass 
8.89&8.32 
Pass 
 
3.2.10 Reproducibility 
The results for reproducibility are presented in Table 23 to Table 25. The method passed 
the reproducibility criteria for all analytes with exception of JWH-018. The method is easy 
to use, can be employed by different analysts. 
Table 23: Analyst one results 
Analyte name Linearity 
R2 
QC1 
Accuracy 
(%) 
QC1 
duplicate 
Accuracy 
(%) 
QC2 
Accuracy 
(%) 
QC2 
duplicate 
Accuracy 
(%) 
THC 0.9951 99.16 86.59 86.07 83.25 
THC-COOH 0.9925 117.87 105.55 96.18 93.15 
JWH-018 0.9952 110.16 103.75 112.78 90.28 
AM-2201 0.9940 104.38 95.09 92.95 89.91 
AB-CHMINACA 0.9954 107.01 109.95 99.07 100.84 
JWH-018 N4-
hydroxypentyl 
0.9948 108.79 99.57 98.51 95.39 
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Table 24: Analyst two results 
Analyte name Linearity 
R2 
QC1 
Accuracy 
(%) 
QC1 
duplicate 
Accuracy 
(%) 
QC2 
Accuracy 
(%) 
QC2 
duplicate 
Accuracy 
(%) 
THC 0.9930 90.58 100.49 83.75 82.75 
THC-COOH 0.9948 98.43 114.77 92.67 87.40 
JWH-018 0.9969 80.03 106.05 111.15 92.96 
AM-2201 0.9905 89.89 108.63 91.68 86.52 
AB-CHMINACA 0.9936 97.68 112.81 109.48 112.03 
JWH-018 N4-
hydroxypentyl 
0.9953 87.16 106.12 97.48 92.31 
 
Table 25: Analyst three results 
Analyte name Linearity 
R2 
QC1 
Accuracy 
(%) 
QC1 
duplicate 
Accuracy 
(%) 
QC2 
Accuracy 
(%) 
QC2 
duplicate 
Accuracy 
(%) 
THC 0.9957 106.08 100.79 108.02 96.74 
THC-COOH 0.9951 97.00 118.43 112.98 117.02 
JWH-018 0.8925 137.07 101.68 71.54 97.30 
AM-2201 0.9968 102.92 105.96 108.80 100.72 
AB-CHMINACA 0.9958 114.39 114.67 119.82 118.46 
JWH-018 N4-
hydroxypentyl 
0.9960 110.25 112.29 118.66 111.06 
 
3.2.11 Dilution integrity 
Dilution integrity results are presented in Table 26. Both dilution methods (method 1 adding 
0.5mL of blank blood to 0.5mL fortified blood, method 2 analysing only 0.5mL of fortified 
blood), are applicable for all analytes and 0.5mL of sample can be used for analysis, as 
after dilution samples are still accurately quantified and ion ratios pass. 
Table 26: Dilution integrity results for QC1 sample 
Analyte name Method 1 
Accuracy 
(%) 
Method 
1 ion 
ratios 
Method 2 
Accuracy 
(%) 
Method 
2 ion 
ratios 
THC 118.94 Pass 102.69 Pass 
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Table 26: (Continued) 
Analyte name Method 1 
Accuracy 
(%) 
Method 
1 ion 
ratios 
Method 2 
Accuracy 
(%) 
Method 
2 ion 
ratios 
THC-COOH 99.37 Pass 96.26 Pass 
JWH-018 114.12 Pass 115.52 Pass 
AM-2201 97.16 Pass 98.18 Pass 
AB-CHMINACA 121.38 Pass 125.04 Pass 
JWH-018 N4-
hydroxypentyl 
99.64 Pass 105.02 Pass 
 
3.2.12 Ruggedness 
The ruggedness of method was investigated by different analysts performing the extraction 
technique and assessing the performance of the calibration curve and QC samples. The 
results are presented in reproducibility section (Tables 23-25). The extraction of samples 
by different analysts showed that the method is reproducible and easy to use for different 
analysts. 
Ruggedness was also investigated by having different analysts prepare pH buffers, mobile 
phases during different days of analysis. This did not influence the results, accuracy of the 
batches.  
Moreover, tests for dilution integrity were carried out (Table 26). The results show that 0.5 
or 1mL of sample can be used for analysis to produce reliable results. The method is 
efficient to use smaller sample volumes, it does not affect the accuracy or ion ratios for 
analytes.  
3.2.13 Stability 
The stability of samples was tested by examining two storage conditions. The results for 
condition 1 (analysing same sample one week apart) is presented in repeatability section 
(Table 21). The results for second storage condition (extracting samples and keeping two 
weeks in refrigerator) , is presented reproducibility subheading, results for analyst 1 (Table 
23). Both storage conditions passed the assigned criteria parameters. This shows that the 
method can be used to analyse samples, that were extracted and kept in the refrigerator for 
up to 2 weeks and sample can be analysed if it was kept in the refrigerator for up to one 
week. This is an important advantage of the method, as often real-life samples cannot be 
analysed during the same day as they were received, the analysis may need to be delayed 
by few days. Based on the tests it seems the delay would not affect the results and analysis 
would still be valid and reliable. 
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3.2.14 Recovery 
Triplicates of low and high concentration samples of set A were made. The average value 
of low concentration and average value of high concentration were used to compare to set 
C results (Table 27). Low concentration was QC1 and high concentration was QC2. 
The recovery for all analytes was below 50%. However, the sensitivity and LOQs for all 
analytes, with exception of JWH-018, passed the required criteria of the method. 
Table 27: Recovery for analytes at low concentration (triplicates) and high concentration 
(triplicates) 
Analyte name 
Average RE at low 
concentration 
(%)(range %) 
Average RE at high 
concentration (%) 
(range %) 
Average 
RE  (%) 
THC 58.87 (26.20 to 79.79) 38.82 (24.44 to 86.36) 48.85 
THC-COOH 48.06 (23.96 to 66.04) 37.47 (26.03 to 46.38) 42.76 
JWH-018 26.63 (20.53 to 31.70) 45.44 (34.44 to 62.23) 36.03 
AM-2201 38.18 (27.43 to 48.07) 61.95 (46.41 to 81.76) 50.06 
AB-CHMINACA 38.14 (23.27 to 50.81) 35.81 (24.55 to 50.18) 36.97 
JWH-018 N4-
hydroxypentyl 
13.01 (9.17 to 16.16) 13.73 (10.64 to 17.03) 13.37 
 
3.2.15 Matrix effect 
Triplicates of low and high concentration samples of set A were made. The average value 
of low concentration and average value of high concentration were used to compare to set 
B results (Table 28). Low concentration was QC1 and high concentration QC2. 
Overall, all analytes experienced ion suppression. However, the methods sensitivity, LOQ 
still passed the required criteria for all analytes, with exception of JWH-018. 
Table 28: Matrix effects for analytes at low concentration (triplicates) and high concentration 
(triplicates) 
Analyte name Average ME at low 
concentration (%) 
(range %) 
Average ME at high 
concentration (%) 
(range %) 
Average 
ME (%)  
THC -25.40  
(-48.72 to 2.71) 
-44.74 
 (-37.24 to -48.70) 
-35.07 
THC-COOH -51.58  
(-44.89 to -59.35) 
-44.49  
(-40.66 to -48.85) 
-48.04 
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Table 28: (Continued) 
Analyte name Average ME at low 
concentration (%) 
(range %) 
Average ME at high 
concentration (%) 
(range %) 
Average 
ME (%)  
JWH-018 -67.97 
 (-65.87 to -71.47) 
-48.63 
 (-28.75 to -62.01) 
-58.30 
AM-2201 -58.01 
 (-54.35 to -62.55) 
-28.59 
 (-3.63 to -45.88) 
-43.30 
AB-CHMINACA -29.19  
(-23.97 to -38.52) 
-24.25  
( -44.56 to 8.01) 
-26.72 
JWH-018 N4-
hydroxypentyl 
-62.12  
(-58.61 to -65.91) 
-56.38 
(-42.08 to -65.46 
-59.25 
 
3.3 THC and THC-COOH concentrations in clotted blood 
Clotted blood was compared to non-clotted blood samples, spiked at same concentration. 
Duplicates of controls and clotted blood samples were analysed, with results of duplicates 
being varied by less than 10% The results for THC and THC-COOH concentration 
differences in venous blood and venous clotted blood is presented in Table 29 and Table 
30. The results for THC seem to indicate that on average THC concentration is higher in 
clotted blood by approximately 1ng/mL compared to non-clotted blood. Moreover, the 
majority of clotted samples had higher THC concentration compared to non-clotted 
samples. THC-COOH, shows a similar pattern to THC, with THC-COOH clotted blood 
samples having on average higher concentration by approximately 5ng/mL compared to 
non-clotted samples. Also, the majority of THC-COOH clotted samples have higher 
concentration than the non-clotted samples. The % difference between clotted and non 
clotted samples for THC is on average approximately 6%, while for THC-COOH is 
approximately 12%. However, there was seven clotted samples for THC and nine clotted 
samples for THC-COOH that had lower concentration compared to their respective controls. 
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Table 29: Results of THC concentrations difference in clotted venous and venous (control) blood. –
difference the clotted blood is lower, + difference clotted blood is higher in concentration 
Sample  THC clot 
(ng/mL) 
THC 
control 
(ng/mL) 
Difference 
(ng/mL) 
Difference 
by (%) 
1 1.78 2.02 -0.24 -11.77 
2 10.37 10.08 0.29 2.86 
3 1.89 2.01 -0.12 -5.97 
4 12.01 9.07 2.95 32.50 
5 1.94 2.20 -0.26 -11.92 
6 2.21 2.20 0.01 0.33 
7 2.38 2.20 0.17 7.82 
8 2.19 2.12 0.06 2.92 
9 14.56 11.61 2.95 25.38 
10 13.92 11.61 2.31 19.88 
11 13.52 11.61 1.91 16.45 
12 2.23 2.54 -0.30 -11.89 
13 2.15 2.54 -0.39 -15.37 
14 10.01 9.64 0.37 3.86 
15 11.05 9.64 1.41 14.66 
16 17.03 19.06 -2.04 -10.69 
17 17.44 19.06 -1.62 -8.50 
18 19.47 19.06 0.40 2.12 
19 29.80 19.06 10.74 56.32 
20 22.27 19.06 3.21 16.83 
  Average 1.09 6.29 
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Table 30: Results of THC-COOH concentrations difference in clotted venous and venous (control) 
blood. –difference the clotted blood is lower, + difference clotted blood is higher in concentration 
Sample THC-
COOH 
clot 
(ng/mL) 
THC-
COOH 
control 
(ng/mL) 
Difference 
(ng/mL) 
Difference 
by (%) 
1 5.49 6.47 -0.98 -15.15 
2 45.53 47.64 -2.11 -4.42 
3 6.46 7.13 -0.67 -9.37 
4 51.76 39.36 12.39 31.49 
5 6.19 4.25 1.95 45.79 
6 6.26 4.25 2.01 47.25 
7 6.33 4.25 2.08 49.01 
8 5.64 4.83 0.81 16.76 
9 63.61 45.96 17.65 38.40 
10 55.69 45.96 9.73 21.16 
11 57.93 45.96 11.97 26.03 
12 5.63 7.86 -2.23 -28.36 
13 5.71 7.86 -2.16 -27.42 
14 43.49 45.75 -2.25 -4.93 
15 50.66 45.75 4.91 10.74 
16 78.98 90.64 -11.66 -12.86 
17 87.05 90.64 -3.59 -3.96 
18 89.94 90.64 -0.69 -0.77 
19 135.33 90.64 44.69 49.31 
20 109.79 90.64 19.15 21.13 
  Average 5.05 12.49 
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4. Discussion 
This research describes the development and validation of LC-MS/MS technique that can 
quantify two natural and four SC in blood. Following method development experiments, the 
method was validated to assure reliability, in line with ISO 17025 guidelines and UKAS 
recommendations. Moreover, the validated method was utilised to study the affects of 
clotting blood on THC and THC-COOH concentrations, with results indicating that clotting 
alters measured concentrations of analytes. 
Pre-method development literature was researched to identify potential ion fragmentation 
pathways relating to THC, THC-COOH and SC.  Numerous studies researching THC or SC 
have utilised the same ions fragmentation pathways, as described in this study (Krotulski et 
al. 2018, Shah et al. 2014, Agilent 2017, Borg et al. 2017). The sample preparation, 
extraction and separation procedure were based on research by Aizpurua-Olaizola et al. 
(2017) but with several modifications to improve recovery and efficiency. The research by 
Aizpurua-Olaizola et al. (2017) provided the starting point for this research. The method 
published in their study utilised an Agilent 1260 LC coupled to an Agilent 6430 MS/MS. This 
method had excellent precision, accuracy and sensitivity. Despite this the column that was 
associated with the Aizpurua-Olaizola et al. (2017) method, Kinetex polar C18, was shown 
to have extremely poor robustness and reproducibility. As a result of this lack of robustness, 
sensitivity and subsequent elongation of the method runtime it was decided that this column 
would not be suitable to complete a validation programme designed to test casework 
samples or SC samples.   
Following these results and using the Phenomenex C18 column, an Agilent Infinity Lab 
Poroshell 120 EC-C18 column was chosen, based on a method developed for analysis of 
THC and THC-COOH by Agilent (2013).This method utilised an Agilent 6430 system and 
achieved a sensitivity of 1ng/mL of THC in whole blood. This technique was further 
optimised into a method that could analyse natural and SC in a single chromatographic run 
at concentrations in blood below 1ng/mL. Following the successful method development, 
using the Agilent Infinity Lab Poroshell column, the validation process was started. The 
parameters that were tested for the quantitative method were accuracy (bias), precision, 
carryover, selectivity and specificity, matrix effect, LOD, LOQ, linearity (calibration model), 
range, recovery, reproducibility, repeatability and ruggedness. These are the parameters 
that need validation to be in line with SWGTOX, UKIAFT and ISO17025 recommendations 
for casework sample analysis. However, there are no universally defined standards or exact 
criteria for all parameters when utilising analytical methods in forensic toxicology in the UK. 
The criteria for the parameters are decided by individual laboratories and should broadly be 
in line with UKAS (United Kingdom Accreditation service) guidelines for best practice in ISO 
17025 accreditation. Prior to the laboratory examination of the method parameters, a 
validation outline was proposed, which included the criteria for each method specification. 
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All the experiments were to be performed on whole blood matrix for which the method is 
intended to be used (SWGTOX 2013, Polettini 2006). 
The data from the validation experiments indicated that the accuracy results for five out of 
six analytes passed the validation criteria, with a failure rate of 0%, while one analyte, JWH-
018, had a fail rate of 2 in 10 for the low QC samples and 1 in 10 for the higher QC 
concentration. Moreover, the precision for all analytes, with exception of JWH-018 passed 
the validation requirements. These results showcase the methods quantitation efficiency, 
and repeatability. The calibration range for all analytes was validated, with a focus on drug 
concentrations of analytes being similar to those encountered in casework settings 
(Ambroziak and Adomowicz 2016, Vaiano et al. 2016). An optimisation of this method was 
that the LOQ validated for analytes was in lower concentrations than methods developed 
by Aizpurua-Olaizola et al. (2017) and Agilent (2013). However, both of the mentioned 
methods were able to analyse 11-OH-THC, alongside THC and THC-COOH, which this 
method cannot. Moreover, the LOQ of this method for THC and several SC was lower and 
more sensitive than numerous studies described in the literature utilising similar 
instrumentation (Hackett and Elian 2009,  Krotulski et al. 2018). Moreover, Hackett and 
Elian (2009) and Krotulski et al. (2018) were only looking at THC and THC-COOH, while 
this method also looks at SC. The validation of dilution integrity demonstrated that lower 
volumes of sample can be utilised for analysis, this is useful in cases requiring repeat 
analysis of sample or instances of low sample availability. The robustness and repeatability 
parameters validated in this method demonstrates its applicability for different analysts, and 
potential use in research or commercial settings. Overall, five out of six analytes (THC, 
THC-COOH, AM-2201, AB-CHMINACA, JWH-018 N4-hydroxypentyl) were fully validated, 
passed all validation criteria. One analyte (JWH-018) did not meet the validation 
requirements for repeatability, LOQ and reproducibility but passed all other criteria, was 
considered only semi-validated. 
One of the major challenges of incorporating research based methods into casework 
settings is the lack of applicability of certain methods to identify all drugs in a polydrug 
sample specifically. Often methods developed in research and applied in real cases only 
quantify ion ratio’s using one qualifier ion (Aldlgan and Torrance, 2016). This can cause 
specificity issues for the analysis of certain analytes, in particular SC, which have similar 
structures, chemistry and fragmentation patterns. Identifying only one qualifier ion for an 
analyte is not reliable as certain analytes can have the same parent and daughter ions, for 
example JWH-122 and JWH-019. Moreover, recently Huestis and LeBeau  have proposed 
a point-based scoring system to be used for the identification of analytes in forensic 
toxicology laboratories (ASB 2019). The recommendations from Huestis and LeBeau state 
that a minimum of 3 ions need to be used for confirmation of an analyte. Two of the analytes 
as qualifiers and one analyte as the quantifier (International Association of Forensic 
69 
 
Toxicologists (TIAFT) 2019). The point-based scoring system is proposed to make the 
identification process of analytes more objective in the forensic toxicology field. A minimum 
of 4 points is required to state that an analyte was identified utilising no more than 3 
analytical techniques working in tandem. For example, analysis of compounds with LC-
MS/MS using dMRM of 3 ions transitions, two qualifiers and one quantifier, receives 4 
points. One point is received for LC separation and a point is received for each ion (TIAFT 
2019, ASB 2019). The risk of utilising fewer ions in identification process is the possibility 
of utilising ions, that belong to another compound other than the target analyte, thus 
mistakenly confirming the analyte. This risk is increased in cases whereby the sample has 
multiple drugs present and more so if these drugs and their metabolites share similar 
structures, chemistry and ion fragmentation pathways. A greater number of ion transitions 
used and more strict criteria employed enables confirmation of an analyte with a higher 
degree of certainty. The method developed and validated in this research confirms an 
analyte using two qualifier ions, while the majority methods for SC and natural cannabinoids 
described in the literature only use one qualifier ion. Moreover, the developed and validated 
method follows the recommendations from Huestis and LeBeau, which are likely to 
circulated to US and European laboratories in the next 12 months. 
The described method can be used for road traffic toxicology (RTT) casework to detect and 
quantify THC for Road Traffic Act 1988 Section 5A. THC is the most commonly detected 
illicit drug in motorist in European countries, and in the United States of America (EMCDDA 
2018, Hartman et al. 2016b, Rooney et al. 2017). The limits for THC in blood vary in several 
countries across Europe, with typical limits ranging from 1-3ng/mL. In the United States the 
majority of limits in each state are set at 5ng/mL. In England and Wales Section 5A of the 
Road Traffic Act 1988 states the limit for THC in blood is 2ng/mL (Department of Transport 
2017, EMCDDA 2018). The developed method can reliably quantify THC concentrations 
between ranges of 0.5-20ng/mL in blood and therefore determine if the THC concentration 
was above or below the Section 5A per se limit. The method can detect and quantify THC-
COOH, the main metabolite of THC. The quantitation and confirmation of THC-COOH in a 
sample, which has THC present, demonstrates that THC was not due to passive exposure, 
confirms the use of THC. This is due to fact that THC-COOH is a metabolite of THC can be 
found only after cannabis consumption and metabolism in the body. The method is also 
relatively cheap and has more efficient sample preparation procedure than methods that 
use GC-MS. One the key steps in sample preparation for GC-MS is derivatisation 
Derivatization is a process by which a compound is chemically changed, producing a new 
compound that has properties applicable to an analytical method. For GC-MS an analyte of 
interest is modified with a derivatization reagent to produce a new product that is more 
volatile, thermally stable and can produce reproducible results. The process of 
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derivatization is time consuming, expensive and the analyte of interest can be lost due to 
contamination from the reagent. 
In the UK, specifications for methods used to quantify blood drug concentrations for the 
purpose of Road Traffic Act 1988 Section 5A analysis are detailed in FSR-C-133. FSR-C-
133 is a guideline proposed by the Forensic Science Regulator in collaboration with 
UKIAFT. It should be noted at that these recommendations are not legally enforceable and 
are at this point still guidelines (Forensic Science Regulator 2020). This method was 
developed with the FSR-C-133 guidelines in mind and it is these requirements that most 
forensic science providers adhere to when testing RTT samples in the UK.  These 
recommendations state that isotopically labelled deuterated standard should be used for 
analytes, which this method follows. The parameters that need to be validated and tested 
are the same ones, as in this methods validation plan. Moreover, it is required that the upper 
quantitation limit be at least 5 times that of the per se limit. Therefore, the minimum 
requirement for the LOQ is 1ng/mL and for the upper concentration limit it is 10ng/mL for 
THC. The validated method has a lower LOQ of 0.5ng/mL with upper concentration limit of 
20ng/mL for THC. This is in line with the requirements stated in the FSR-C-133. In addition, 
QC at legal limit is required to be used and the developed method is utilising a QC of THC 
at the legal limit of 2ng/ml. The only criteria of FSR-C-133 that this method does not meet 
is the requirement that the method be accredited by UKAS to ISO 17025 standard. Due to 
the costs associated with accreditation, the developed method has not accredited to ISO 
17025 standards but has been validated based on ISO 17025 and UKIAFT guidelines. 
A method that analyses THC for RTT is important not only due to widespread use of THC 
in society but also due to the risks associated with cannabis use and driving. THC produces 
impairment on driving by affecting cognitive and psychomotor performance (Bondallaz et 
al. 2016, EMCDDA 2018, Hartman and Huestis 2013). Motorists under the influence of 
cannabis drive slower, have difficulty in driving exercises such as tracking and lane position 
variability (Hartman and Huestis 2013, Lenné et al.  2010, Ronen et al. 2008,). Moreover, 
the ability to perform divided attention tasks, a fundamental skill in driving, declines when 
under the influence of cannabis as does concentration span and reaction time (Battistella 
et al. 2013, Bondallaz et al. 2016, Hartman and Huestis 2013, National Highway Traffic 
Safety Administration (NHTSA) 2017,).  
The developed and validated method was also utilised to research the effects of blood 
clotting on concentrations of THC and THC-COOH and test methods robustness. These 
two analytes were chosen as THC is highly prominent in motorists, where the exact 
concentration of the drug is vital to know and has legal ramifications in light of Road Traffic 
Act 1988 Section 5A limits. The concentrations, which were analysed for THC were at the 
legal limit and above it (2, 10 and 20ng/mL). In the UK blood collected for analysis of drugs, 
including THC, is preserved in vials with preservatives of sodium fluoride and potassium 
71 
 
oxalate or ethylenediaminetetraacetic acid (EDTA) (Faculty of Forensic and Legal Medicine 
2020). Potassium oxalate and EDTA are anticoagulants, however if the blood sample is 
taken improperly or not sufficiently mixed with the preservative and anticoagulant then blood 
clotting can occur. Blood clotting is a complicated process, with many reactions taking place 
simultaneously (appendices, clotting cascade section). In short, when blood clots a solid 
mesh is formed that is composed of platelets and other blood cells, mainly red blood cells, 
to prevent excess loss of blood. It has been shown by Huestis et al. (1992a, 1992b) that 
THC concentration is significantly different in plasma compared to whole blood. Huestis et 
al. (1992a, 1992b) conducted research, whereby participants consumed cannabis and after 
cessation of smoking, blood samples were collected for analysis. Whole blood as well as 
plasma was analysed for pharmacological data, which demonstrated concentration 
differences for plasma and whole blood. THC and THC-COOH concentrations in whole 
blood are lower by approximately half compared to plasma, due to high plasma protein 
binding and poor cannabinoid distribution into erythrocytes (Schwilke et al. 2008). This 
suggest that during sample partition THC will favourably dissolve into the water rich solution 
as opposed to the protein portion of a blood sample. Moreover, the haematocrit value 
influences how much of THC, THC-COOH is present in whole blood (Giroud et al. 2001). 
The analysis of venous clotted blood compared to venous non-clotted blood seem to 
indicate, that THC and THC-COOH concentrations are artificially altered and on average 
raised by the clotting process, with THC-COOH being affected more than THC. The exact 
mechanism of why it is happening is not clear. One possible explanation is THC and THC-
COOH are unable to bind to proteins with a high iron content. It has previously been 
suggested that the heme protein in red blood cells prevents cannabinoid binding. The 
research by Huestis et al. (1992a, 1992b) and pharmacological data in literature does 
demonstrate universally that THC and THC-COOH have high affinity to plasma proteins but 
not to red blood cells. It is only in settings whereby the blood plasma ratio is higher that THC 
does not remain protein bound, by contrast non iron containing protein such as albumin 
demonstrate strong binding affinity for THC.  
Overall, the clotting study indicates that clotted blood samples analysed for THC and THC-
COOH alters measured concentration and typically tends to overestimate the concentration 
of drug analyte in clotted blood compared to concentrations in whole blood. This is an 
important in RTT, as analysis of clotted blood samples for THC may lead to unreliable 
results, and result in a miscarriage of justice or an incorrect conviction. For THC on average 
by approximately 6% clotted samples are higher in concentration compared to non clotted 
samples, while for THC-COOH clotted samples are 12% higher compared to non clotted. 
Moreover, a further study with cannabis users is needed to confirm the findings of this study 
and to find an average percentage difference of venous clotted and venous non clotted 
blood, so it could be used in road traffic casework. 
72 
 
The concentrations for SC that can be reliably quantified by the method are in the range of 
0.25-10ng/mL in whole blood. This concentration range can be applicable to analyse 
samples of SC users, as the SC concentrations are often below 1ng/mL in whole blood. The 
case studies of SC users, who are treated in emergency departments, commonly have low 
concentrations of SC present in blood, typically below 10ng/mL, as the drugs are more 
potent, so less drug dosage  is needed for adverse side effects to occur (WHO 2017). The 
designed method could analyse blood samples from users, who had experienced adverse 
side effects of SC. The low detection limits of the method would allow to analyse samples 
with a relatively long detection window of 4-6 hours. After the first few hours SC usually are 
below 1ng/mL, and the method can detect and accurately quantify SC to 0.25ng/mL. 
Moreover, the method detects different generation SC and often the products consumed by 
users have mix of SC, is rare for them to have only one SC present (Presley et al. 2016, 
Marusich et al. 2018). 
The method has its limitations, it cannot accurately quantify JWH-018 all the time, with a 
failure rate of 1 in 10 for high concentrations and 2 in 10 for low concentrations. It should 
however be noted that must casework laboratories operate methods with a QC failure rate 
of approximately 10% (SWGTOX 2013, Elliott et al. 2018). The performance of the QC’s in 
relation to JWH-018 could be due to variation in extraction and not using deuterated internal 
standards for this compound, to control for the differences in extraction. Another drawback 
of the method is only one qualifier ion can be used for JWH-018 N4-hydoxypentyl, none of 
the second qualifiers tested were stable, with all qualifying ions displaying different ion ratios 
in different concentrations. This is an issue that has been widely described for SC, as some 
analytes have the same parent and daughter ions and only the ion ratio and 
chromatography can differentiate them. For instance, JWH-122 and JWH-019 can only be 
identified by chromatography (Scheidweiler and Huestis 2014). Having two qualifiers for 
JWH-018 N4-hydroxypentyl could yield a more reliable confirmation of the compound, 
address the issue of some SC and their metabolites having identical ion transitions. 
Further optimisation of the extraction procedure could improve the method. Currently, the 
method has high matrix effects for all analytes, which is compensated by their respective 
internal standards. The optimisation of the solvents and pH buffer for the extraction 
procedure might yield better recovery and lower ion suppression. Also, a lower sample 
volume than 0.5mL would be beneficial. The samples taken for RTT cases are 
approximately 10mL of whole blood, which is divided into two samples A and sample B 
(Faculty of Forensic and Legal Medicine 2020). In theory the volume received by the 
laboratory should be approximately 5mL of whole blood per sample, but in practice this is 
not always the case as there may be issues sampling blood from the subject. A lower 
volume of sample used for extraction would mean the analysis could be repeated and that 
more sample volume could be devoted to the screening and analysis of other drugs if 
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needed. The addition of more SC, including ones that are most prevalent in the UK in last 
few years would make the method more beneficial to the UK toxicology market. In the UK 
there is no national forensic body, independent companies analyse samples for 
toxicological results. The major toxicological companies have no incentive to analyse SC, 
as is not widely prominent, not financially beneficial. Only government bodies like FEWS, 
WEDINOS and work carried out by researchers in universities, indicate what SC are 
currently used and how widespread they are. A method that can analyse THC for road traffic 
toxicology and popular SC would address this issue and help to further determine what the 
true usage of SC is among the general populace.  
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5. Conclusion 
A method for analysis of natural and synthetic cannabinoids has been developed for LC-
MS/MS. It has been validated for THC, THC-COOH, AM-2201, JWH-018 N4-hydroxypentyl 
and AB-CHMINACA. The method was validated based on guidelines from UKIAFT, 
SWGTOX and ISO 17025. Moreover, the method follows the guidelines of FSR-C-133, with 
exception of being accredited. This method can be used for analysis of RTT casework 
samples, for per se limits of THC for Road Traffic Act 1988 Section 5A. In addition, SC can 
be analysed at levels usually found in users and coroners’ cases. The SC can be analysed 
alongside THC in RTT, to show prevalence of SC in general population. Lastly, a clotting 
side study for THC and THC-COOH was carried out, which indicates that clotting alters the 
concentrations of these analytes, clotted samples are not reliable to use, where accurate 
quantitation is required. The side study showcases the utility of the method to be used for 
whole blood as well as clotted blood. 
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Appendices 
1. Column issue 
Kinetex polar C18 column robustness issues. The column at first performed well (for 
almost a month), the extracted samples for THC and THC-COOH eluted in less than 10 
minutes (Figure 28). However, after few calibration lines run on the column, the column 
lost its robustness. The retention times shifted by over 6 minutes for both compounds, 
for compounds to elute the gradient had to be changed and run extended to atleast 17 
minutes from previously 11 minutes (Figure 29). Moreover, the sensitivity has 
decreased for the analytes, 0.5ng/mL of THC could not be detected anymore (Figure 
30).  The reason for the issue is not clear as following recommendations by the 
manufacturer (Phenomenex), how to clean the column nothing changed, they could not 
comment how come such a drastic change in retention time occurred. As the issue was 
not resolved and because the column was not reliable, sensitivity decreased a new 
column was chosen for the method. 
 
 
 
 
 
  
 
Figure 28: Result from Kinetex polar C18 column at the beginning of method development. THC 
and THC-COOH elute in less than 10 minutes. 
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Figure 29: Results after less than a month of using the Kinetex polar C18 column. The retention time 
has shifted for both analytes, THC-COOH elutes at 11min, while THC at 14min. The mobile phase 
that was used was not changed, the extraction procedure was the same as before, no changes were 
made to the method or solvents that were used. 
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Figure 30: Results for 20ng/mL of THC. The top picture demonstrates the response area for THC  
quantifier ion and retention time, when the method was working with Kinetex polar C18. The bottom 
picture presents what response was for THC quantifier ion after unknown column issues occurred. 
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2. Clotting cascade  
Figure 31 describes the clotting cascade process. 
 
 
Figure 31: Clotting cascade process. The intrinsic pathway, it is activated when blood is exposed to 
collagen, or other damaged surfaces. The end result is factor IXa (with PF3) will join to factor VIIIa 
to form a complex, which activates factor X. The extrinsic pathway is activated as the damaged 
endothelial cells release factor III, greater the damage more of it is released. Factor III and factor 
VIIa form a complex, which activates factor X. The convergence of pathways to activate factor X 
begins the common pathway. In the end fibrinogen is converted into fibrin strands, which help secure 
platelets, erythrocytes and form a clot. 
